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Abstract 
Coronary heart disease (CHD) is a chief cause of death in westem 
countries. It has been suggested that apolipoprotein A-I (apoA-I) and 
apolipoprotein BlOO (apoB100), the principal protein component of high density 
lipoprotein (HDL) and low density lipoprotein (LDL), respectively, are the most 
significant parameters for assessment of CHD risk. Our laboratory has tried to set 
up an immunodiagnostic assay for measurement of serum apoA-I and apoB100. 
Human apoA-I and apoB100 were purified from serum. Rabbits were 
immunized with these apolipoproteins for polyclonal antibody production. 
Hybridoma cell lines were produced which secret anti-apoA-I and anti-apoB100 
monoclonal antibodies. These monoclonal antibodies are only specific to their 
target lipoproteins and they bind identically to purified apolipoproteins and 
native lipoproteins. 
Using the monoclonal and polyclonal antibodies, a sandwich ELISA was 
developed for the measurement of apoA-I. In this assay, microtiter plates were 
pre-coated with protein A. Polyclonal antibodies were immobilized onto the solid 
phase through the binding with protein A. Monoclonal antibodies were 
conjugated to alkaline phosphatase, as detecting antibody. The assay has a 
working range of 0.2 to 1.2 ^ig/ml of apoA-I and the intra- and inter-assay 




ApoA-I Apolipoprotein A- I 
ApoB 100 Apolipoprotein B100 
CHD Coronary Heart Disease 
DMSO Dimethyl Sulfoxide 
EDTA Ethylene DiamineTetraacetic Acid 
ELISA Enzyme Linked Immunosorbent Assay 
cFA Complete Freund's Adjuvant 
iFA Incomplete Freund's Adjuvant 
FCS Fetal CalfSerum 
HAT Hypoxanthine Aminopterin Thymidine 
HDL High Density Lipoprotein 
IDL Intermediate Density Lipoprotein 
IgG Immunoglobulin G 
LCAT Lecithin Cholesterol Acyltransferase Transferase 
LDL Low Density Lipoprotein 
LPDS Lipoprotein Depleted Serum 
PBS Phosphate Buffer Saline 
PBSMT Phosphate Buffer Saline (with 3% dry Mi lk, 0.1% Tween20) 
PBST Phosphate Buffer Saline (with 0.1% Tween20) 
PEG Polyethylene Glycol 
PMSF Phenylmethyl Sulfonyl Flouride 
pNpp p-Nitrophenylphosphate 
RCT Reverse Cholesterol Transport 
SDS-PAGE Sodium E>odecylsulphate-Polyacrylamide gel electrophoresis 
SMCC N-Succinimidyl 4-CN-maleimidomethyl)-cyclohexane-1 -carboxylate 
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Introduction to Lipoprotein and Apolipoprotein 
1.1 Lipoprotein structure and classitication 
Lipoproteins are water-soluble macromolecular complexes of lipids 
(triglycerides, cholesterol and phospholipids) and specific proteins, referred to as 
apolipoproteins. A major function of the lipoproteins is to transport lipids through the 
vascular and extravascular body fluids. Their general structure is globular. Within the 
core of the lipoprotein particle are the more hydrophobic lipids, viz, the esterified 
cholesterol and the triglycerides. On the outer layer are the more polar lipids, such as 
phospholipids, free cholesterol and the apolipoproteins; with their charged groups 
pointing out towards the water molecules. 
Human plasma lipoproteins are commonly divided into five major classes 
based on their densities (Figure 1.1). They are chylomicrons, very low density 
lipoproteins (VLDL, d<1.006g/ml), intermediate density lipoproteins (IDL, d=1.006_ 
1.019g/ml), low density lipoproteins (LDL, d=1.019-1.063g/ml) and high density 
lipoproteins (HDL, d=1.063-1.21g/ml). 
1.2 Apolipoprotein A-I and BlOO 
1.2.1 Apolipoprotein A-I 
Apolipoprotein A-I (apoA-I) is the major protein component of HDL. Its 
primary structure was first reported by Brewer et al. (Brewer et al. 1978). It is a 
single polypeptide chain of 243 amino acid residues with a molecular weight of 28 
kDa. It contains approximately 55% alpha helix, 8% pleated sheet, and 37% random 
coil. ApoA-I is synthesized as a preproapolipoprotein with 24 amino acids attached 
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Figure 1.1 The classification, composition, and density ofthe lipoproteins 
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to the N-terminus of the mature protein (Duverger et al. 1993; Law and Brewer 
1984). PreproapoA-I undergoes co-translational cleavage of the N-terminal 18 amino 
acids to produce proapoA-L ProapoA-I, containing the propeptide sequence Arg-His-
Phe-Trp-Gln-Gln, accounts for approximately 4% of the total fasting plasma apoA-I. 
There are other possible post-translational covalent modification reported in the 
literature. These include phosphorylation and myristoylation (Law and Brewer 
1984). Polymorphism of apoA-I, demonstrated by isoelectric heterogeneity, is in 
most cases thought to be the result of post-translational modification. ApoA-I has 
been separated into four polymorphic forms by isoelectric focusing and into six 
forms by two-dimensional electrophoresis P^estmck et al. 1980; Zannis et al. 1980). 
1.2.2 Apolipoprotein BlOO 
ApoB100 is a major protein component of VLDL, IDL, LDL, and a unique 
lipoprotein, lipoprotein (a). ApoB100 is one of the largest proteins known, 
containing 4536 amino acid residues with a molecular weight of 550 kDa (Chen et al. 
1986; Knott et al. 1986; Law et al. 1986). ApoB100 has 19 potential N-linked 
glycosylation sites, of which only 16 are actually glycosylated (Yang et al. 1989). 
ApoB100 contains 8-10% carbohydrate in the form of galactose, mannose, N-
acetylglucosamine, and sialic acid residues (Swaminathan and Aladjem 1976). 
Analysis of secondary structure indicates that apoB100 contains 43% of alpha helix, 
21% P-sheet, 20% random structures, and 16% P_turns (Garnier et al. 1978). There 
are twenty five cysteine residues in apoB100 which are quite asymmetrically 
distributed and are located mainly in the N-terminal region. Sixteen of the cysteine 
residues are involved in disulfide linkage (Yang et aL 1990). Immunoelectron 
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microscopic analysis of apoB100 on LDL suggests that the protein is extended and 
spans at least a hemisphere of the lipoprotein particle surface (Chatterton et al. 1991). 
1.2.3 Biological functions of apolipoprotein 
It is now established that the apolipoproteins of the various lipoproteins 
regulate lipoprotein metabolism and determine their unique roles in lipid metabolism 
(Table 1.1). Several major functions have thus far been ascribed to specific 
apolipoproteins. One well-established function is their involvement in the transport 
and redistribution of lipids among different tissues. The delivery of lipids to specific 
cells involves the recognition of specific apolipoproteins by cell surface lipoprotein 
receptors. ApoB100 has been shown to mediate the interaction of lipoproteins with 
LDL receptors of the liver and extrahepatic tissues (Chan 1992; Mahley 1988). A 
second function of specific apolipoproteins involves their role as cofactors for 
enzymes of lipid metabolism. The LCAT (lecithin:cholesterol acyltransferase) 
reaction is activated by apoAI (Ikeda et al. 1994). This cofactor appears to activate 
LCAT by providing a suitable lipid or liposome interface upon which the enzyme 
can work. An additional function for apolipoproteins involves their role in the 
maintenance of the structure of the lipoproteins. Various apolipoproteins, e.g., 
apoB100 and apoA-I, appear to stabilize the micellar structure of the lipoproteins and 
function, in association with phospholipids on the surface of the particles, to provide 
a hydrophilic surface. 
1.3 Evidence linking apoA-I and BlOO with atherosclerosis 
The strong association between risk of coronary heart disease (CHD) and 
apolipoproteins has been well documented in several large epidemiological studies 
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Table 1.1 Apolipoproteins: their properties and functions 
Apolipoprotein Molecular mass Plasma Function 
concentration, 
mg per 100 ml 
AI 28 016 80-160 Activation of 
LCAT; 
Detergent properties 
AII 17 414 20-55 ？ Activation of 
hepatic lipase 
B48 264 000 0-2 Secretion of 
chylomicrons 
BlOO 550 000 60-160 Secretion ofVLDL; 




CI 6 600 3-11 ？ 
CII 8 850 1-7 Activation of 
lipoprotein lipase 
c m 8 800 3-23 ？ Inhibition of 
hepatic uptake of 
chylomicrons and 
VLDL 
E 34 100 2-6 Hepatic clearance of 
chylomicron 
remnants and IDL 
(a) 300 000-700 000 1-100 ？ Inhibitor of 
fibrinolysis 
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(Stampfer et al. 1991; Levinson and Wagner 1992; Sigurdsson et al. 1992; Coleman 
et al. 1992). All of these studies drew the same conclusion; i.e., ApoA-I is 
significantly lower and apoB100 significantly higher in myocardial infarction 
survivors. 
Transgenic mice expressing human apoA-I and apoB100 have previously been 
created (Rubin et al. 1991a; Callow et al. 1994). The C57BL/6 mice expressing the 
human apoA-I transgene had higher plasma concentrations of human apoA-I and 
HDL than non-transgenic mice and were resistant to diet-induced atherogenesis 
(Rubin et al. 1991b). The presence of the high expressing human apoB100 transgene 
was associated with a 2.5-fold increase in LDL cholesterol and a 15-fold increase in 
proximal lesions of the coronary arteries compared with non-transgenic mice 
(Callow et al. 1995). 
1.4 The roles of apoA-I and BlOO in the development of atherosclerosis 
In seeking a mechanism for the anti-atherogenic effect of HDL, most attention 
has been directed at the role of HDL in reverse cholesterol transport (RCT) (Oram et 
al. 1987; Hara and Yokoyama 1992; Fruchart et al. 1994). The interaction of HDL 
with its receptor appears to facilitate the transport of cholesterol from cells to HDL 
particles. Ligand blotting study has provided evidence that this receptor is a 110 kDa 
membrane protein (Schmitz et al. 1985). Binding of apoA-I to this receptor can 
stimulate the production of diacylglycerol which can activate protein kinase C and 
promote the translocation of cholesterol from intracellular compartments to the 
apoA-I containing lipoprotein (Figure 1.2) (Theret et al. 1990). The receptor-bound 
HDL particles are then released back into the extracellular fluid. This reversible 
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Figure 1.2 ApoA-I mediated Reverse cholesterol transport. ApoA-I in the 
HDL is proposed to bind to HDL receptor, and triggers a 
signaling pathway to translocate intracellular cholesterol to cell 
membrane. HDL, itself acts as cholesterol acceptor and 
transport these excess cholesterol to liver. 
PLC, phospholipase C; PLD, phospholipase D; IP3, inositol 
trisphosphate; PKC, protein kinase C 
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association allows HDL to sequester cholesterol and remove it from the cell. In a 
recent study, synthetic peptides can mimic apoA-I in both binding to cell-surface 
receptors and clearing cholesterol from cells (Mendez et al. 1994). Using monoclonal 
antibodies, a region of apoA-I within or adjacent to residues 140-150 is found to be 
responsible for the ability of apoA-I to promote intracellular cholesterol efflux 
(Sviridov et al. 1996). 
The common initiating step of the LDL oxidation is the peroxidation of the 
polyunsaturated fatty acid within the LDL molecule (Steinberg et al. 1989), probably 
as a result of the production of oxygen free radicals. Lipid peroxides formed in this 
way spontaneously decompose to short-chain aldehydes which can attach covalently 
to apoB100 amino-acid residues (Fong et al. 1987), particularly the lysine amino 
f 
groups (Steinbrecher 1987). Besides the LDL receptor, macrophage has another 
receptor, the scavenger receptor, which is responsible for the accumulation of 
oxidized LDL and the formation of foam cell (Figure 1.3). The chemical change to 
apoB100, and not the lipid moiety of the particle, is the crucial component 
recognized by the scavenger receptor (Parthasarathy et al. 1987). This scavenger 
pathway — unlike the normal LDL receptor — is not down regulated when the cell has 
sufficient lipid for its own maintenance fNagelkerke et al. 1983). Therefore, 
macrophages can become literally bloated with lipid droplets if there is enough 
modified LDL in the nearby extra-cellular fluid. 
1.5 Measurement of human serum lipoproteins as an assessment of risk for 
coronary heart disease (CHD) 
In the last several decades, it has been customary to utilize the measurement of 
LDL and HDL cholesterol in profiling the CHD risk ofan individual (Kannel et al. 
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1971). Of the recent biochemical markers added to the constellation of atherogenic 
index, the apolipoproteins, especially apoA-I and apoB100, appear to be the most 
straight forward indicators for use in the clinical laboratory (Srinivasan and Berenson 
1995; Bhatnagar and Durrington 1991; Laker and Evans 1996). In the editorial of 
Clinical Chemistry (1996, issue 42)，Dr. Sniderman concluded, quoted, ‘After so 
much emphasis on cholesterol as the hallmark for risk assessment, is it possible to 
change to apolipoproteins without confusion and loss of credibility? If change is in 
the patient's interest, if change leads to more precise diagnosis and treatment, if 
change makes our practice simpler and in the end less expensive, should we not 
welcome change rather than resist it?’ (Sniderman and Cianflone 1996). The 
reference limits for apoA-I and apoB100 as proposed by the Framingham offspring 
study are both at 1.2g/L (Contois et al. 1996a; Contois et al. 1996b). Subjects with 
semm apoA-I level lower than 1.2g/L or apoB100 higher than 1.2g/L are more likely 
to have CHD than subjects with apoA-I higher than 1.6g/L or apoB 100 lower than 
l.Og/L. 
1.6 Aims of this study 
When immunoassay was first introduced for measuring apolipoproteins in 
serum (Schonfeld and Pfleger 1974), antibodies specific to apolipoprotein A-I were 
polyclonal since they were raised in animals. The animal, usually a rabbit or a goat 
was immunized and bled. The resultant antiserum was used as the reagent. The 
immunoglobulin G made from these antisera carried a mixture of several hundred 
different types of antibodies. Each of these antibodies has its own characteristics and 
hence, the property of polyclonal antibody is heterogeneous. Consequently, 
standardization of the immunoassays that based on antisera is difficult. To overcome 
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the above problems, monoclonal antibody could be a useful alternative. With its pre-
defined specificity, cross-reactions due to mixture of antibodies against irrelevant 
antigens could be eliminated. 
In this study, both polyclonal and monoclonal antibodies against apolipoprotein 
A-I and BlOO will be produced. They will be used to set up a direct ELISA for the 
quantification of apoA-I and B in human serum. The antibodies, before being 
employed, will be characterized mainly in terms of specificity. A major problem in 
solid phase immunoassays is the denaturation of the protein ligand bound onto a 
plastic surface. To overcome this problem, an alternative ELISA method, protein A-




Purification of Apolipoprotein A-I and BlOO and 
Production of Polyclonal Antibodies 
2.1 Introduction 
2.1.1 Purification of apolipoprotein A-I and B from human serum 
Human serum contains over 100 proteins ranging in concentration from 40 
mg/ml (albumin) to almost undetectably low levels. Table 2.1 shows the major 
human serum proteins, their normal concentrations and biological functions. 
ApoA-I is the major protein of HDL, comprising about 70% ofthe total HDL 
proteins. Isolation of apoA-I generally includes ultracentrifugation to isolate HDL, 
delipidation with organic solvent to obtain apoHDL proteins free of lipid, and 
various chromatographic separation of apoA-I from other HDL peptides such as gel 
filtration, ion exchange (Beg et al. 1989; Law et al. 1983) or preparative reversed 
phase HPLC (Hughes et aL 1988). 
The method for apoB100 isolation is quite similar to apoA-I. ApoB100 
purification is more difficult than apoA-I due to its extreme size and lability. 
Moreover, apoB100 is highly hydrophobic and insoluble in aqueous solutions. 
Attempts to solubilize apoB100 in aqueous buffers by using chemical modification-
i.e., succinylation or maleylation- have resulted in a low yield of soluble protein 
(Gotto et aL 1968; Scanu et aL 1968). Another way to solubilize apoB100 is the 
addition of detergents or guanidine-HCl to stabilize the apolipoprotein in solution 
(Socorro and Camejo 1979; Steele and Reynolds 1979). 
12 
Table 2.1 Major human serum proteins 
Normal 
Protein Molecular concentration, Biological functions 
Mass mg per 100 ml 
Albumin ‘ 66 000 3500-5500 Osmotic function; protein~~ 
reverse, transport of ions, 
pigments, etc. 
Immunoglobulin G 150 000 800-1700 Major semm and tissue 
antibody; 
When aggregated activates 
both pathways of 
complement 
Immunoglobulin M 970 000 50-320 First antibody to appear 
after antigenic stimulation; 
When bound to antigen 
activates classical pathway 
of complement 
Immunoglobulin A 160 000 100-500 Antibodies with restricted 
specificity; 
Poor activator of alternative 
pathway of complement 
Haptoglobin 86 000 400 Hemoglobin binding 
Fibrinogen 341 000 200-450 Precursor of fibrin, major 
protein of clots 
Transferrin 80 000 200-400 Iron binding and transport; 
Unsaturated transferrin is 
bacteriostatic 




reduces platelet activation 
Apolipoprotein BlOO 550 000 65-155 Main protein component of 
LDL and VLDL; 
Regulates lipoprotein 
metabolism 
a 1 -Antiproteinase inhibitor 54 000 200-400 Inhibitor of neutrophil 
elastase also trysin, 
chymotrypsin 
a2-Macroglobulin 820 000 150-350 Inhibits most 
endoproteinases 
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2.1.2 Immunization for polyclonal antibodies production 
There is no single method for animal immunization that guarantees an ideal 
product. Nevertheless, certain principles can be adopted which form the ground rules 
for an immunization protocol. 
For practical reasons, rabbits is a good choice for the routine production of 
polyclonal antisera. However, most laboratory rabbits are outbred and, hence, they 
respond individually, so more than one animal should be used for immunization. 
The immunogenicity of an antigen can be enhanced by the addition of 
adjuvant. Most adjuvants are of two main types: colloidal (e.g. aluminium 
hydroxide), or oils that can be used to form an emulsion with an aqueous antigen 
preparation (e.g. Freund's complete and incomplete adjuvants). These are mixed 
thoroughly with the immunogen prior to immunization. This is important, as it has 
been calculated that only 0.1% of the antigen administered in a single dose actually 
reaches the immune system in the absence of adjuvant. Some adjuvants contain 
additional components that enhance immune response. For example, complete 
Freund's adjuvant (cFA) contains heat-killed mycobacteria in addition to oil and an 
emulsifying agent. Complete Freund's adjuvant should be used for the first 
immunization but should be replaced by incomplete Freund's adjuvant (iFA, oil and 
emulsifying agent only) for all subsequent immunization to avoid excessive 
inflammation. 
For a soluble protein immunogen mixed with Freund's adjuvant, a dose of 0.5-
1.0 mg/animal is recommended for rabbit immunization (Harlow and Land 1988). 
The route of injection should also be considered and guided by the injection volume, 
components of the immunogen and the desired rate of release. For the rabbit, large 
volume injections are normally given at multiple subcutaneous sites on the back. If 
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slow release ofthe immunogen is desired then the injection should be intramuscular. 
After initial (or priming) injection, the majority of antibodies produced belong to the 
class M immunoglobulins (IgM). This is known as the primary response. The initial 
priming of the host animals will establish the immuno-memory for this particular 
antigen. Ifthe antigen is reintroduced later, the antibody response is faster, stronger, 
persists for a longer period and is qualitatively different. This is known as the 
secondary response. The most important observation in this secondary response is 
the shift ofantibody class from IgM to immunoglobulin G (IgG). The response ofthe 
third and subsequent injection broadly resembles that of the secondary response 
(Figure 2.1). The length of time between immunization can influence the affinity of 
the antibodies. After immunization and subsequent initial antibody production, 
antigen levels will become progressively reduced. When a low concentration is 
reached, only high affmity B cells will be activated and clonally expanded. The 
longer the interval between immunizations, the lower the residual antigen and the 
greater the preferential selection for high-affinity B cells. The interval between the 
initial and other boosters is recommended to be between 3-6 weeks (Harlow and 
Land 1988). 
2.1.3 Antibody purification 
If the antibody is to be used without a label being attached to it, partial 
purification of it may be sufficient. If it is to be labeled, then it should be more than 
80% pure or the labeling process will be inefficient. If the antibody is to be used for 
in vivo application, then it must be free of any toxins (pyrogens). The strategy for 
antibody purification also depends on the class of the desired antibody. For IgM, 
because ofits large molecular weight, it can be easily isolated by size-exclusion 
15 
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Figure 2.1 Immunogenicity and antibody production 
1. A primary immune response to a soluble antigen induces first 
an IgM antibody production 
2. A booster injection induces a marked increase in the IgG 
antibody level 
3. A second booster injection soon after the previous one (3 
weeks) is less effective in IgG antibody production 
4. An increased delay (6 weeks) between two successive boosts 
yields more antibodies 
(From Paraf, A.，and G. Peltre. 1991. Immunoassays in Food and Agriculture. 
Kluwer Academic Publishers, Dordrecht, The Netherlands.) 
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column. Hereafter we shall describe the commonly used methods for IgG 
purification. 
2.1.3.1 Ammonium sulfate precipitation 
Ammonium sulfate precipitation is a classical method for subfractionating 
serum protein. While it may give some purification, it is mainly a method for 
concentrating antibody. In general, antibodies are precipitated between 40 to 60% 
ammonium sulfate saturation. The precipitated antibody can then be redissolved in 
phosphate buffer saline (PBS) and dialyzed before any further manipulations. Excess 
ammonium sulfate will interfere with most of these flirther purification procedures. 
2.1.3.2 DEAE and QEAE Sepharose 
These are positively charged matrices designed to remove negatively charged 
albumin, which will be the major contaminant in the antibody preparations. DEAE 
and QEAE are available attached to fast-flow matrices such as Sephadex, Sepharose, 
or acrylamide bead. In addition, FPLC columns containing similar matrices (MonoQ ^ 
columns) are now available. IgG molecules bind poorly to such matrices and elute 
first in a gentle salt gradient while negatively charged albumin stays on the column. 
The advantage of this step is low-cost removal of the bulk of the albumin without 
exposing the antibody to extremes ofpH. 
2.1.3.3 Protein A and Protein G 
Protein A is the method that has found widest acceptance in antibody 
purification. In most cases, other steps such as ammonium sulfate or DEAE are 
unnecessary. Protein A is a 42-kDa protein found on the cell walls of Staphylococcus 
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aureus, which binds to the Fc region of a wide range of antibody subclasses from 
many species (Langone 1982). While crude preparations of S. aureus may be used, 
protein A is generally coupled to various matrices such as Sepharose for use in 
column chromatography as this method is more convenient than using centrifugation 
to remove the cell/immunoglobulin complex. However, protein A binds poorly to the 
mouse IgGi subclass, the human IgG3 subclass, and most rat monoclonal antibodies. 
To overcome this problem, protein G was introduced. Protein G is a 30- to 35-kDa 
protein isolated from the cell wall of P-hemolytic streptococci of the C or G strains 
(Kronvall 1973). Less is known about protein G than about protein A, primarily 
because protein G was not purified until 1984 (Bjorck and Kronvall 1984). Many 
antibodies from species or subclasses that do not bind well to protein A bind very 
well to protein G. Table 2.2 summarize the affinity of protein A and G for a spectrum 
of antibody sources. 
2.1.3.4 Affinity chromatography 
Affinity chromatography is generally used for isolating polyclonal antibodies 
from serum. This approach can be divided into two basic types, positive and 
negative. Negative selection is more common in which the protein suspected to be 
cross-reacting is immobilized on a gel matrix. The contaminating antibody then 
binds onto the column. The desired antibody, without cross-reaction to the 
immobilized ligand, will appear in the throw-through. 
In the case of positive selection, the analyte is bound onto a solid matrix and 
the antibody sample is passed over the immobilized analyte at neutral pH. After 
18 
Table 2.2 Binding affinity of Protein A and Protein G to Fc regions of 
various immunoglobulin. S, strong affinity; W, weak affmity; 
W/S, weak overall affinity but much greater than that for 
Protein A; NB, no binding. 
Binding affinity 
Species Immunoglobulin Protein A Protein G 
class/subclass 
Human IgG S S 
IgM W NB 
IgD NB NB 
IgA W NB 
IgGl S S 
IgG2 S S 
IgG3 W S 
IgG4 S S 
Mouse IgG S S 
IgGl W W/S 
IgG2a S S 
IgG2b S S 
IgG3 S S 
Rat IgG W W/S 
IgGl W W/S 
IgG2a NB S 
IgG2b NB W 
IgG2c S S 
Bovine IgGl W S 
IgG2 S S 
Sheep IgGl W S 
IgG2 S S 
Goat IgGl W S 
IgG2 S S 
Rabbit IgG S S 
Guinea pig IgG S W 
Porcine IgG S W 
Horse IgG W S 
Dog IgG S W 
Chicken IgG NB NB 
Cat IgG S W 
Monkey (rhesus) ^gG S S 
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washing the column, irrelevant antibody is removed in the running buffer. Antibodies 
specific to the analyte are then eluted using high or low pH or chaotropic agents. One 
disadvantage of this method is that when a truly high-affinity antibody is in the 
sample, it will be extremely difficult to elute it without using conditions which may 
destroy the antibody or the immobilized ligand (Table 2.3). 
2.2 Methods 
2.2.1 Purification ofHDL and LDL from human serum 
Fasting serum samples were obtained from the Department of Chemical 
Pathology, Prince of Wales Hospital. Lipoproteins were isolated by ultracentrifugal 
flotation. To prevent lipoprotein degradation during ultracentrifugation, PMSF 
(0.015% final concentration) and EDTA (0.04%) were first added into the semm. 
Semm was centrifuged at 38,000 r.p.m. at 4°C for 24 hours in a Beckman 42.1 rotor. 
In this run, chylomicrons and VLDL floated to the top while other serum proteins 
and lipoproteins migrated to the bottom of tube. The layer ofVLDL and chylomicron 
was removed and a salt solution was then added to raise the background density to 
1.019 g/ml. This salt solution was made by dissolving 153 g NaCl, 354 g ofKBr and 
100 [ig EDTA in 1 liter of water giving a density of approximately 1.33 g/mL The 
amount of salt solution needed to be added could be calculated by the following 
equation: 
D - D 1 
V2 = VI 
D2-D 
Where V1= initial volume of solution, V2= volume of heavy solution to be added, 
D= required density, D1= original density, D2= density of the heavy solution (the 
density of serum is assumed to be 1.006 g/ml). The mixture was then centrifuged at 
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Table 2.3 Elution of antibodies from immunoadsorbents 
Elution conditions Comments 
Diethylamine, 0.05 M, pH 11.5 Compatible with deoxycholate; often the 
method of choice for membrane antigens 
Glycine-hydrochloride, pH 2.2-2.8 Incompatible with deoxycholate. Poor 
recoveries and aggregation of some 
membrane 
Sodium thiocyanate, 3.5 M Traces will inhibit iodination and coupling 
with fluorecein; remove by extensive 
dialysis 
Guanidine-hydrochloride, 6 M Very strong denaturing; efficient eluant but 
may cause severe aggregation 
Urea, 2-8 M, pH 7 Heating in urea causes carbamylation of 
protein 
Magnesium chloride, 2-5 M Incompatible with deoxycholate 
Propionic acid, 1 M More effective than HC1 at same pH, 
possibly owing to slight detergent action. 
May cause denaturation and irreversible 
aggregation 
1 M Ammonia, pH 11.5 
Ethylene glycol (50%, v/v), at pH 11.5 Polarity-reducing agent; disrupts 
hydrophobic interactions 
Dioxane (10%, v/v), at acid pH Polarity-reducing agent; disrupts 
hydrophobic interactions 
Electrophoresis, isoelectric focusing Avoids denaturing conditions; somewhat 
slow and cumbersome 
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38,000 r.p.m. at 4 � C for 24 hours. The top layer was pipetted out and the density of 
the remaining infranatant was adjusted to 1.06 g/ml by adding salt solution. LDL 
with a density cutoff from 1.019 to 1.06 g/ml would float to the top after 
centrifugation at 38,000 r.p.m. at 4 � C for 48 hours. HDL was also isolated by the 
same method using a density cutoff ofl.08-L2g/ml. The lipoproteins collected were 
dialyzed overnight at 4°C against 150 mM NaCl, 1 mM EDTA and 0.02% NaN3 
_ ) . 
2.2.2 Purification of apolipoproteins 
Purified HDL and LDL were delipidated in 20 volumes of ice-cold ethanol-
ether (v/v 3:1) ovemight at 4°C by gentle rocking. The insoluble apolipoproteins 
were collected by centrifugation for 20 minutes at 720 g, 4^C. The organic phase was 
decanted and the protein pellet was washed once with ethanol-ether (v/v 3:1) and 
then twice with cold anhydrous diethyl ether. Apo-HDL was solubilized in 150 mM 
NaCl, 20 mM Tris, 1 mM EDTA, 0.02% NaN3 and 6 M Urea (pH8). Apo-LDL was 
solubilized in 150 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, 0,02% NaN3, 10% 
glycerol and 2% SDS (pH7.2). The traces of ether in the sample were removed by 
blowing a gentle stream of nitrogen over the sample. 
ApoA-I was isolated by size chromatography on Sephacryl S-200. Delipidated 
HDL was applied onto a 1.6 x 100 cm column. Elution was carried out at 4°C in 150 
mM NaCl, 20 mM Tris, 1 mM EDTA, 0.02% NaN3 containing 6 M Urea (pH8). The 
fractions in the main peak were pooled and dialyzed against PBS at 4°C. The column 
flow rate was 10 ml/hour. The purity of the apoA-I preparation was checked by 
12.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
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ApoB100 was isolated by size chromatography using Sepharose CL-4B. 
Delipidated LDL was applied onto a 2.6 x 100 cm column. Elution was carried out at 
room temperature in 150 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, 0.02% NaN3 
and 0.1% SDS (pH7.2). Fractions corresponding to the main peak were pooled and 
dialyzed extensively against PBS at room temperature in order to remove excess 
SDS. The dialysis was performed at room temperature because the SDS would 
precipitate at 4°C. The column flow rate was 8 ml/hour. The purity of the apoB100 
preparations was checked by 5% gel SDS-PAGE. Protein concentration was 
determined by the method ofBradford (Bradford 1976). 
The qualities of the purified apolipoproteins were examined by double 
immunodiffusion and immunoelectrophoresis using standard antiserum obtained 
commercially. 
2.2.3 Immunization of rabbit with apolipoprotein A-I and BlOO 
Four male New Zealand white rabbits (2-2.5 kg, two for apoA-I and two for 
apoB100) were housed in individual metal cages and allowed free access to rabbit 
chow and water. A 12-hour light and dark cycle was maintained in the holding area. 
For each rabbit, 0.5 mg apolipoprotein was dissolved in 0.5 ml PBS which was then 
mixed with 0.5 ml cFA. The water-oil mixture was then emulsified by mixing the 
solution a few dozen times between two syringes connected with a double-hub 
needle (Herbert 1973). The stability of the emulsion was tested by allowing a drop of 
the mixture to fall onto the surface of a beaker of water, which should remain as a 
discrete globule. A total of 1 ml of emulsion was injected in four subcutaneous sites 
on the back skin of the rabbit (0.25 ml for each site). Injections were repeated at a 
three-week interval using same amount and volume of antigen, but cFA was replaced 
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by iFA. Three days after the last booster (three boosters totally), blood sample was 
collected from the ear vein. Around 40 ml blood could be obtained from each rabbit. 
Blood was allowed to clot at room temperature for 2 hours then at 4 � C ovemight. 
Serum was obtained by centrifugation at 2,000 g for 10 minutes and was stored in 1 
ml aliquots at -20 °C. 
2.2.4 Enzyme-linked immunosorbent assay (ELISA) 
The presence of specific anti-apoA-I and B antibodies in the antisera was 
determined by indirect ELISA. 200 [i\ of apolipoprotein (25 ^ig/ml) in coating buffer 
(15 mM Na2CO3, 34.8 mM NaHCO3, pH9.6) was added to each well of a 96-well 
ELISA plate. The tray was capped and incubated at 37°C for 1 hour. The coating 
solution was emptied and the wells were washed three times with PBST (PBS with 
0.1% Tween20) with 5 minutes between each wash. The empty sites were saturated 
by incubating with 200 i^l 1% BSA in PBS at 37�C for 1 hour. Plates were then 
washed three times with PBST. Antiserum (100 i^l) at various dilutions was added 
(initial dilution of 1:200 and serially two-fold diluted to 1:204800) and incubated at 
37�C for 1 hour. The plate was washed five times with PBSMT (PBS with 0.1% 
Tween20 and 3% dry milk) in order to remove unbound materials. Detecting 
antibody (100 ^1 of rabbit anti-mouse IgG with alkaline phosphatase (ALP) 
conjugated, 3000-fold diluted from stock) was then added to each well and incubated 
at y f C for 1 hour. After washing three times with PBSMT and two times with 
PBST, each well was incubated with 100 i^l substrate solution pNpp (10 mM p-
nitrophenylphosphate disodium salt in 0.1 M diethanolamine, pH10.3, containing 0.5 
mM MgCl2) at room temperature. Color was developed in the dark for 30 minutes 
and the absorbance at 405 nm was measured in an ELISA plate reader. The titer of 
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the antiserum was defined as the dilution of the antiserum which will give an 
absorbance of 0.5. 
2.2.5 Purification oflipoprotein specific immunoglobulin from antisera 
2.2.5.1 Salt fractionation 
Saturated ammonium sulfate solution was prepared by dissolving 1000 g 
ammonium sulfate in 1000 ml distilled water at 50^C and allowed to stand overnight 
at room temperature and adjusted to pH7.2 with diluted ammonia solution. 
Antiserum was diluted two-fold with PBS and saturated ammonium sulfate solution 
was added slowly while stirring to a final concentration of 45% saturated (v/v). If 
this was done too quickly, ‘hot spots' would form which would denature the 
antibody. The mixture was stirred for a further 20-30 minutes at room temperature to 
allow full precipitation of protein. The protein precipitate was centrifuged down at 
3000 g for 30 minutes at room temperature. The supernatant was discarded and the 
precipitate was redissolved in a minimum volume of PBS. The dissolved protein was 
dialyzed against five changes of PBS (pH8.0) at 4°C and the protein concentration 
was determined (Lowry et al. 1951). 
2.2.5.2 Purification of immunoglobulin by Protein A affinity chromatography 
Any aggregates in the antibody sample were removed first by filtering through 
a 0.45 i^m membrane. Before applying the sample to the protein A column (1 ml 
protein A-Sepharose), the column was equilibrated with 3 bed volumes of PBS. 
According to the description of the manufacturer, protein A-Sepharose could bind 
4.5-9 mg immunoglobulin per ml of gel. The antibody sample was applied to the 
column without exceeding the maximum binding capacity of the gel. The unabsorbed 
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materials were washed out with five volumes ofPBS or until no material appeared in 
the effluent. Excessive washing should be avoided if the interaction between the 
antibody of interest and the ligand was weak. The absorbed immunoglobulin was 
then eluted by three column volumes of elution buffer (0.1 M citric acid, pH3.0). The 
effluent was collected in fractions to which sufficient amount of neutralizing buffer 
(1.0 M Tris-HCl pH9, 80 i^l per ml fraction) was added to bring the pH up to around 
7. To regenerate the protein A column, the column was mn through an alternate 5 ml 
cycle of 0.1 M sodium acetate, pH4.5, containing 500 mM NaCl and 0.1 M Tris, 
pH8.5 containing 500 mM NaCL Finally the column was re-equilibrated with 0.1 M 
PBS before the next run. If the column was to be stored, the column was equilibrated 
with 10 ml 20% ethanol. By measuring absorbance at 280 nm, the effluent fractions 
with protein were analyzed by 12.5% SDS-PAGE. The fractions containing the 
immunoglobulin fractions were pooled and dialyzed against PBS (pH8) containing 
0.2% NaN3. 
2.2.5.3 Isolation of specific antibody by lipoprotein-coupled affmity chromatography 
Purified HDL or LDL were coupled onto cyanogen bromide (CNBr)-activated 
Sepharose 4B. 5.5 g CNBr-activated Sepharose 4B was weighed out and suspended 
in 1 mM HC1 (1 g freeze-dried powder gives about 3.5 ml final volume of gel). The 
gel was supplied freeze-dried in the presence of additives, which could be washed 
out by 1 L of 1 mM HC1 on a sintered glass filter. Lipoproteins with a equivalent of 
136 mg of protein content were dissolved in 27.5 ml coupling buffer (0.1 M NaHCO3 
pH8.3 containing 0.5 M NaCl). The coupling ratio recommended by the 
manufacturer was 7 mg protein per ml gel dissolved in 1.43 ml coupling solution. 
The lipoprotein was mixed with the gel and the mixture was rotated end-over-end for 
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1 hour at room temperature. After washing away the excess protein by five volumes 
of coupling buffer, the gel was transferred to 0.1 M Tris-HCl to block the unreacted 
active groups. For complete removal of uncoupled lipoprotein, the column was 
washed with 4 cycles of alternative high and low pH buffer. Each cycle consisted of 
0.1 M acetate at pH4.0 followed by 0.1 M Tris-HCl at pH8.0 each containing 0.5 M 
NaCl. This procedure ensured that no free lipoprotein remained ionically bound to 
the geL The coupled gel was equilibrated in PBS (pH8.0) containing 0.2% NaN3 
before the first run. 
The immunoglobulin purified by protein A affinity column was applied onto 
the lipoprotein-coupled Sepharose 4B (19.25 ml of gel volume). The unbound 
immunoglobulin was washed out with PBS (pH8.0) and the lipoprotein-specific 
immunoglobulin was eluted by 0.1 M citric acid (pH3.0). 
2.3 Results 
2.3.1 Purification of apoA-I and B100 
When HDL apolipoprotein was fractionated by Sephacryl S-200 gel filtration 
(Figure 2.2), only one main peak was observed (peak I). By electrophoretic analysis 
(Figure 2.3), peak I showed a single band with an apparent molecular weight of 28 
kDa corresponding to the size of apoA-I (Figure 2.4). From 100 ml human semm，35 
mg of apoA-I could be isolated. The reactivity of the purified apoA-I with standard 
goat-anti-human apoA-I serum was examined by double immunodiffusion (Figure 
2.5). Precipitin line was observed between standard antiserum and purified apoA-I, 
proving that the purified protein was apoA-I. The intensity of the precipitin line, 
when compared with the positive controls, suggests the binding affinity of the 
purified apoA-I is comparable to standard apoA-I and native HDL. 
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Figure 2.2 Sephacryl-S 200 gel filtration chromatography of HDL apolipoproteins. 
10 mg of protein in 150mM NaCl, 20mM Tris, lmM EDTA, 0.02% 
NaN3 and 6M Urea (pH8) was applied and eluted at 10 ml/hr with the 
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Figure 2.3 SDS-Polyacrylamide (12.5%, reducing) gel electrophoresis 
of ApoA-I. (A) Standard: albumin, 67 kDa; (B) Low 
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Figure 2.4 Standard curve for determination of protein molecular weight. Six 
references standards were mn and their positions were plotted ( • ) 
and the linear best fit line was drawn. The Rf value for the 
purified protein (Peak I) then was calculated and plotted on the 
line ( • ), and the molecular weight was calculated. 
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Figure 2.5 Double immunodiffusion of purified apoA-I, standard 
apoA-I and HDL with standard anti-apoA-I serum. The 
middle well contained 0.2 ml standard goat-anti-human 
apoA-I serum. Well A and E contained 10 i^l of standard 
apoA-I (1 mg/ml); well C contained 10 |il of ten-fold 
diluted human serum; well B and D contained 10 ^1 of 
purified apoA-I (1 mg/ml); well F was the control 
containing PBS. 
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The elution profile of the LDL apolipoproteins fractionated by SepharoseCL-
4B gel filtration chromatography is shown in Figure 2.6. A main peak (jpQdk I) was 
observed. The material from peak I was pooled and further analyzed by SDS-PAGE. 
A single band was present with a molecular size similar to apoB100, i.e., 550 kDa 
(Figure 2.7). This pure protein was referred to as apoB100. From 100 ml human 
serum, 78 mg of apoB100 was purified. Immunoelectrophoresis was performed to 
examine the reactivity of the purified apoB100 to standard anti-apoB100 serum. 
From Figure 2.8, the precipitin line formed with standard antiserum proves that the 
purified protein is apoB100. The left shift of positive control LDL was due to the 
larger molecular weight ofLDL than apoB100. 
2.3.2 Purification of immunoglobulins from rabbit anti-apolipoprotein sera 
Rabbit antisera against human apoA-I and apoB100 were produced as 
described in the method section. Their titers as determined by ELISA are shown in 
Figure 2.9 and 2.10. For anti-apoAI, an absorbance of 1.0 was obtained when the 
antiserum was diluted 1500-fold. Activity then gradually decreased with increasing 
dilution. The absorbance decreased to 0.5 when the antiserum was diluted to 55,000-
fold which was defined as the titer of the antiserum. When it was diluted to 400,000-
fold, the anti-apoA-I activity reached background level (absorbance 0.1). In the case 
of the anti-apoB100 serum, maximum antibody activity was observed at 700-fold 
dilution. Activity became undetectable when the dilution was increased to 400,000-
fold. Using the same criterion as mentioned above, the titer of the anti-apoB100 
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Figure 2.6 SepharoseCL-4B gel filtration chromatography of LDL apolipoproteins. 
20 mg ofprotein in 150mM NaCl, lOmM NaH2PO4, lmM EDTA, 0,02% 
NaN3, 10% glycerol and 2% SDS (pH 7.2) was applied and eluted at 8 
ml/hr with 150mM NaCl, lOmM NaH2PO4, lmM EDTA, 0,02% NaN3 
and 0.1% SDS (pH7.2). The material from peak I was pooled for further 
analysis. 
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Figure 2.7 SDS-Polyacrylamide (5%, reducing) gel electrophoresis of 
peak I from apo-LDL separation. (A) Standard: albumin, 67 
kDa; (B) High molecular weight marker; (C) Low molecular 
marker; (D) Peak I form the elution of aopLDL. 
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Figure 2.8 Immunoelectrophoresis of purified apoB100 and LDL with 
standard goat-anti-human apoB100 serum. Well A contained 10 
^1 of LDL (1 mg/ml) and well B contained 10 i^l of purified 
apoB100 (1 mg/ml). The goat-anti-human apoB100 standard 
semm was placed in a trough cut in the 2% agarose. 
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Figure 2.9 Anti-apoA-I activity in rabbit antiserum taken on day 3rd after the third 
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Figure 2.10 Anti-apoB100 activity in rabbit antiserum taken on day 3rd after the 
third booster. The control wells were pre-coated with BSA of same 
protein concentration. 
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From 10 ml anti-apoA-I serum, 125.3 mg of protein was extracted from the 
45% ammonium sulfate precipitation. The protein was applied onto a protein A-
affinity column and 80.3 mg of IgG was isolated. The IgG fraction was further 
purified on a HDL-coupled Sepharose 4B column and 2.08 mg of HDL-specific IgG 
was obtained (Figure 2.11). By protein determination of the samples before and after 
the HDL-affmity purification, it was estimated that some antibodies were retained in 
the column. These materials probably have a high affinity for HDL as they were not 
eluted by the 0.1 M citric acid. In order to elute these high-affinity materials, stronger 
reagents were used. 4 M magnesium chloride (pH7.2), 3.5 M sodium thiocyanate, 6 
M urea (pH7) were tried and could not elute any of these high-affinity antibodies out, 
but dioxane (10%, v/v) could elute approximately 200 \xg protein. By 12.5 % SDS-
PAGE analysis, these proteins contained some IgG together with some other protein 
contaminants (Figure 2.12). 
From 10 ml anti-apoB100 serum, 132 mg of protein was obtained after 45% 
ammonium sulfate precipitation. From this precipitate, 85.6 mg of pure IgG and 1.27 
mg LDL-specific IgG were purified (Figure 2.13). The 12.5 % SDS-PAGE analysis 
of the purified polyclonal antibodies is presented in Figure 2.14. Two bands appeared 
in the antibody samples with the apparent molecular weight of 55 kDa and 25 kDa. 
These are presumably the heavy chain and light chain of the antibody molecule, 
respectively. 
2.4 Discussion 
Apolipoprotein A-I and apolipoprotein BlOO are two of the main proteins in 
human serum. Their normal concentrations are both around 120 mg per 100 ml 
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Figure 2.11 Purification of HDL-specific IgG from anti-apoA-I serum on 
HDL-coupled Sepharose 4B. The material eluted by citric 
acid was pooled for SDS-PAGE analysis. 
39 
駕:;':::::':”:^^"'':輪_一:^#^'”'’、 
- v ^ : ' ; , ; ; , - ; ; : ; / ; . 一 “ ; : ， 』 1 “ 參 " 一 一 、 、 • : : 、 “ 〜 # ， , : ” 〜 
.:::::','::"';':^^il ^ ^ , ' 、 ： 
' ' - " - ' ； - ； - ： - ' : M $ i ^ : - ‘： ： ： 、 ， 
' 、 ' 、 “ . . 耐 . 讓 丨 曾 丨 丨 丨 伊 M^^^^^. 
‘ ^ ^ ^ ‘ ^ ^ ^ * 1 ' 
^^ ^^ B^  ^ ^^^^^ ,^^^^~' 
|lll|||il||||||||||i|i 
1111111¾^ 
iiiiiiiiiiiii^ iiiiiiiiilii;ii iiiiiiiiiiii!iilii!iiililili :¾:;:;;:;> ¾;¾¾¾¾:;?^  iiiii^ iiiii；；； 
:：；：；：；!：；：：-；：：：：>；；：;；-：；：：：>5>：0；^^ 
_i__i_____^^ 
i i l i i i i i M ^ 
:'••::•::•：；：；：'；>'；：：；：>；：^；^ 
lilililililllliBwi^ ^^ ^ 
• - ---..--^ A&a&a. •':.' ‘ ‘ 
" ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ l ^ ^ ^ . 
" ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m . _ 1 _ 1 1 _ i _ 丨 1 1 1 , i l i : i _ i _ i i : : i i i P i i * i * i ^ :^•:iiii^ ilil^ liiiiiiii^ i^i：^  
:>^ -::.;:¾¾¾¾;¾::¾ • .. . • • • . --<my^mmmmrnmmm^imMmmm^^ ^^ ::::;;;¾-¾¾¾¾:;¾¾:?¾¾^  >：：：；；：；：：：^；；：：：® 
^ ^ ^ ^ ^ ^ ^ ^ ^ K 
、HG、& V …�…、、:：¾¾,;:- '->^i^,..^>rm>,,.,. .W::,;J::��;”A.��:, 
兹1；$滋乡金5!黎1凝：^?^^攀錢_资__5释资^^—錄;丨簿翁發凝,凝錄$簽鐵§?_丨^^絲珍絲;；絲《__纖$;努舞^^^^1^纪_縿资丨丨藥 
l i l ^ M P W _ _ ^ M i r t W _ S i l i i ^ B 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B 
:•:丨:丨:竭:丨丨资:丨丨丨:丨:魏丨;丨:缀:_丨丨丨丨錄;痛丨丨;丨:丨缀丨_魏丨:;缀1_丨_丨丨_1^ 
A B C D 
Figure 2.12 SDS-Polyacrylamide (12.5%, reducing) gel electrophoresis 
of proteins eluted by 10% dioxane. (A) proteins eluted by 
0.1 M citric acid; (B) proteins eluted by 10% dioxane; (C) 
low molecular weight marker; (D) albumin. 
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Figure 2.13 Purification of LDL-specific IgG from anti-apoB 100 serum 
on LDL-coupled Sepharose 4B. The material eluted by 
citric acid was pooled for SDS-PAGE analysis. 
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Figure 2.14 SDS-Polyacrylamide (12.5%, reducing) gel 
electrophoresis of purified rabbit polyclonal 
antibodies. (A) Standard: albumin, 67 kDa; (B) 
Low molecular weight marker; (C) HDL-
specific antibody; (D) LDL-specific antibody. 
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100 ml human semm as starting material, 35 mg apoA-I and 78 mg apoB100 were 
obtained. The yield percentage, presuming 120 mg per 100 ml as the original 
concentration, was 29.17% for apoA-I and 65% for apoB100. The low percentage of 
apoA-I indicated a certain amount of apoA-I was lost. 
Ultracentrifugation is not an ideal method for isolating lipoproteins. The loss of 
apoA-I from HDL during ultracentrifugal isolation has been well documented. In 
these reports, the loss of apoA-I was found to be about 30% (Gurry et aL 1976; 
Fainaru et al. 1976; Mahley and Holcombe 1977) and reached as much as 50% 
(Fainaru et al. 1975). The loss of apoA-I from HDL by other isolation methods, such 
as precipitation and gel filtration chromatography (Rooke and Skinner 1979; Jahani 
et aL 1980), appears to be smaller. These findings suggest that some specific 
problems may be associated with ultracentrifugation. 
Several factors unique to ultracentrifugation that could facilitate the loss of 
apoA-I from HDL have been suggested. They are wall effects (rotor configuration 
and tube type), high ionic strength of the ultracentrifugation medium, low 
temperature during ultracentrifugation, and ultracentrifugal force. Wall effects occur 
when the floating or sedimenting particles contact the centrifuge tube while traveling 
along their radial paths. When this happens, the impact or chemical interaction along 
the tube surface may cause the loss of apoA-I from HDL. Conventional systems of 
isolating lipoproteins by ultracentrifugation involve the addition of inorganic salt to 
the ultracentrifugal solvent to increase background densities. This addition of salt 
greatly increases the ionic strength of the solution. High ionic strength could be 
responsible for the loss of apoA-I from HDL. When lipoproteins are cooled, as 
during an ultracentrifugal run, the lipid components can undergo phase changes 
(Small et al. 1980). The structure of the lipoprotein can change at 4°C and thus could 
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cause a loss of apoA-I from HDL. Lastly, during ultracentrifugation, the sedimenting 
or floating particles are subjected to the high pressure generated in the fluid column 
by centrifugal force. ApoA-I at an air-water interface can be driven into aqueous 
solution by increasing surface tension (Shen and Scanu 1980). Since increasing the 
hydrostatic pressure acting on HDL particles may be equivalent to increasing the 
surface tension on the surface monolayer, this may be another mechanism which is 
responsible for the loss of apoA-I during ultracentrifugation. Some researchers have 
shown that apoA-I, once free in solution, will self-associate, and that self-associated 
apoA-I is slower to reassociate with lipid (Massey et al. 1981; Osborne and Brewer 
1977). This would tend to enhance the separation of apoA-I from HDL. If 
monoclonal antibody specific to apoA-I is available, it is a better way to purify 
apoA-I by affinity chromatography, otherwise ultracentrifugation remains to be the 
most popular method. 
One of the difficulties in apoB100 purification is the protein's lability. In a 
structural study of apoB100, the N-terminal (residues 1 to -1,000) of apoB100 
molecule was found to consist almost exclusively of trypsin-accessible peptides 
which was exposed on the surface of the LDL molecule (Yang et al. 1986). In order 
to inhibit the activity of trypsin, 0.015% PMSF (a serine protease inhibitor) was 
added to the serum. With the pre-treatment ofPMSF, no proteolysis ofapoB100 was 
found (Figure 2.7). If the treatment with PMSF was eliminated, several bands would 
appear in the SDS-PAGE analysis with smaller molecular weights (Figure 2.15). 
Serine protease-mediated proteolytic digestion is suggested to be the main cause of 
apoB 100 degradation observed in other studies. 
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Figure 2.15 SDS-Polyacrylamide (5%, reducing) gel electrophoresis of 
apoB100 purified with and without the pre-treatment of 
PMSF. (A) low molecular weight marker; (B) apoB100 
purified with the pre-treatment of PMSF; (C) apoB100 
purified without the pre-treatment of PMSF; (D) albumin. 
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In the elution profiles of apo-HDL and apo-LDL, only one main peak was 
observed. HDL and LDL contain 20 to 30% of proteins other than apoA-I and 
apoB100. HDL contains apoAII, apoE and apoC. LDL also contains apoC and apoE. 
The apparent lost ofthe other apolipoproteins in our chromatographies may be due to 
the dilution of these minor components in gel filtration chromatography. Moreover, 
due to the small size of these apolipoproteins, i.e., 6-8 kDa, they may be lost at the 
end of the chromatographic runs. 
The major contaminant of antibody purification from serum is albumin. In 
normal serum, 60% ofthe protein content is albumin. After 45% ammonium sulfate 
precipitation of anti-apoA-I and anti-apoB100, nearly all albumins were removed 
(Figure 2.14). The purification efficiencies of the HDL- and LDL-specific antibodies 
can be estimated by assuming the normal IgG concentration in rabbit semm is 10 
mg/ml and the percentage of antigen-specific antibody is 5% to the total IgG. 
Assuming these, the calculated purification efficiency is 41.6% for HDL-specific 
antibody and 25.4% for LDL-specific antibody. 
There are several factors that contribute to the success of an immunoaffinity 
purification. The most crucial is the affinity of the antibody to the antigen. 
The affinity of the antibody to the antigen is the most worrisome of the 
problems encountered with immunoaffinity purification. The ideal antibody is one 
that has a high affinity to the antigen and whose binding can be reversed by a simple 
and gentle change in an easily manipulatable variable such as pH. The binding of 
antibody to antigen takes place by the formation of hydrogen bond, electrostatic or 
coulombic interaction, van der Waals force, or hydrophobic interaction. A high-
affinity antibody is likely to interact with its antigen by some or all of these non-
covalent bonds. To elute this antibody, low pH buffer is not enough. In this study, 
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more extreme conditions were needed (10% dioxane) to elute the high-affinity 
antibody from the HDL-coupled affinity column. It indicates that the antibody and 
HDL are held together not only by electrostatic interaction but also the hydrophobic 
interaction. In this case, the 10% dioxane not only disrupted the hydrophobic 
interaction between the antibody and antigen but probably also damaged the solid 
phase bound HDL. Apolipoproteins are bound onto lipoproteins mainly by 
electrostatic and hydrophobic interaction. The amphipathic helix is a secondary 
structural motiffound commonly in apolipoproteins (Segrest et aL 1974). This is a a-
helix with opposing polar and nonpolar face. The polar face of the helix is exposed to 
the aqueous solution and interacts with the polar head of the phospholipid 
electrostatically. The nonpolar face of the helix is buried into the lipid layer and is 
held by the alkyl chains of phospholipid through hydrophobic interaction. If both of 




Production of monoclonal antibodies against apolipoprotein A-I and BlOO 
3.1 Introduction 
3.1.1 What is monoclonal antibody? 
The monoclonal antibody era began in 1975 with a report in Nature by Kohler 
and Milstein entitled 'Continuous culture of fused cells secreting antibody of pre-
defined specificity’ (Kohler and Milstein 1975). They reported that they developed a 
technique to fuse the B-spleenocyte and myeloma ^)lasmacytoma) cell together to 
produce offspring cells with the desirable characteristics of both parent cells. The 
myeloma cell provided the genes for continued cell division in culture, whilst the B-
spleenocyte provided the functional immunoglobulin genes. The cell line with these 
properties was called hybridoma. A monoclonal antibody may be defined as a 
uniform and homogeneous antibody directed against a single epitope or antigenic 
determinant, and produced continuously from one cell clone. 
In this regard, monoclonal antibodies produced by a single clone of B cells 
have four distinctive advantages over antiserum as an analytic reagent. (1) they have 
uniform affinity and specificity in binding, (2) the antibodies are homogeneous, (3) 
monoclonal antibody can be produced in unlimited quantities, and (4) it obviates the 
need of a pure immunogen for immunization because selection of antibody can be 
performed during the production process. 
•j 
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3.1.2 The basic methodology 
The basic principles involved in the production of monoclonal antibodies are 
illustrated schematically in Figure 3.1. The process involves five major steps: 
immunization, fusion, selection, cloning, and production. 
3.11.1 Immunization of host 
Mouse, rat, and human are the only three main animal species used for 
monoclonal antibody production. It is not possible to make hybridomas from outbred 
animals such as rabbits, sheep, and goats, as suitable myeloma lines are not available 
from these animals. The mouse is usually the preferred species, because (1) it is 
convenient to raise, (2) suitable mouse myeloma lines are available, and (3) the life 
cycle of the mouse is relatively short (gestation time 21 days; first mating at 6-8 
weeks). BALBc mice are the animals of choice because there are several compatible 
myeloma lines. 
3.1.2.2 Cell lines required for fusion 
The cell line used for fusion must be immortal and it should be a myeloma (or 
plasmacytoma) cell, e.g., P3-X63-Ag8-653, Sp2/0-Agl4 (Sp2), and P3/NSl-Ag4-l 
QS[S-1). In myeloma cell, the endoplasmic reticulum system is well established which 
will enable them to secrete large amounts of antibody. On the other hand, it is better 
to select a myeloma cell line which cannot secret its antibody, otherwise its heavy 
chain and light chain will hybridize with those of the B cell, as the result, various 
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Figure 3.1 The general procedure for monoclonal antibody production. Spleen 
cells from immune mice are fused with HGPRT- myeloma cells 
using PEG. The cells is grown in HAT medium. Hybrids are tested 
for production of antibody of the desired specificity, and cloned by 
limiting dilution. The established clone is grown in culture or 
injected into mice for bulk production of monoclonal antibody. 
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3.1.2.3 Fusion 
The fusion of cell membranes occurs at very low frequencies when cells are 
brought into close contact with each other but this fusion rate can be increased by the 
use of substances called fusogens. The original fusogen used was Sendai vims but 
this has now been superseded by polyethylene glycol (PEG) (Pontecorvo 1975), 
HO(CH2CH2O)nCH2CH2OH n 二 6-60 
PEG is a hydrophilic compound which can remove the hydration shell from the 
cell surface. At 50% PEG (w/v), all water molecules in a solution becomes 
associated with PEG. The lack of cell surface water favors hydrophobic interaction 
between membrane lipids and cell fusion occurs between adjacent cells (Wojcieszyn 
et aL 1983). PEG may be obtained in molecular weight range from 200 to 20,000. It 
is toxic to cells and low molecular weight PEG is more toxic than high molecular 
weight PEG. Most successful fusions have been performed with PEG in the 
molecular weight range of 600-6000 (Davidson et aL 1976; Kelbe and Mancuso 
1981). PEG concentration below 30% hardly produces any hybridoma, however, 
over 50% toxicity becomes overwhelming. The optimal concentration of PEG was 
found to be 50% (Galfre and Milstein 1981). Both fusion frequency and cytotoxicity 
increase with time of exposure to PEG. Lower concentration of PEG (30-35%) can 
be tolerated by the cells for a longer time (7 minutes) than higher concentration (50% 
for only 1-2 minutes) (Gefter et al. 1977). Nevertheless, in most established 
protocols, a high concentration of PEG (50%) and a short period of exposure (1 
minute) are used (Lane 1985). The pH of the PEG solution has also been shown to 
affect fusion frequency (Sharon et al. 1980). Maximal numbers of hybridoma are 
obtained at pH8.0-8.2. The speed at which the PEG is added to induce fusion does 
not appear to be too critical. Many published protocols suggest the use of PEG at 
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37°C, successful fusions have also been reported at 4°C. The ratio of spleen:myeloma 
cells used for fusion can range from 10:1 to 2:1. 
3.1.2.4 Selection ofhybrids 
When a cell mixture contains spleenocytes and myeloma cells is subjected to 
fusion, we would expect other types of fusions such as lymphocyte-lymphocyte or 
myeloma cell-myeloma cell, or even higher multiples of these. The most common 
selection procedure was devised by Littlefield in 1964 (Littlefield 1964). Littlefield's 
procedure depends on the fact that when the main biosynthetic pathway for 
guanosine is blocked by the folic acid antagonist aminopterin, there is an alternative 
'salvage' pathway in which the nucleotide metabolites hypoxanthine or guanine can 
be converted to guanosine monophosphate via the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRT) (Figure 3.2). Cells lacking HGPRT die in a 
medium containing hypoxanthine, aminopterin and thymidine (HAT medium) 
because both the main and salvage pathways are blocked. However, a HGPRT' cell 
can be made to grow in HAT medium if it is provided with the missing enzyme by 
fusion with a HGPRT+ cell. Selection of HGPRT' myeloma is performed by using the 
toxic base analogue 8-azaguanine or 6-thioguanine, which is incorporated into the 
DNA via HGPRT. Because the salvage pathway is not normally essential for cell 
survival, mutants that lack HGPRT will continue to grow while cells that possess 
HGPRT will die. The hybrids, fused by a HGPRT' myeloma cell and a HGPRT+ B 
cells, can survive in HAT selection medium. 
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Figure 3.2 Metabolic pathways relevant to hybrid selection in medium 
containing hypoxanthine, aminopterin and thymidine (HAT 
medium). When the main synthetic pathways are blocked with 
the folic acid analogue aminopterin (*), the cell must depend on 
the ‘salvage, enzyme HGPRT and thymidine containing the 
toxic base analogues 6-thioguanine or 8-azaguanine, which are 
incorporated into the cell via HGPRT. Only HGPRT' cells 
survive. HGPRT" cells cannot grow in HAT medium unless they 
are fused with HGPRT+ cells. 
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3.1.2.5 Screening assay 
As not all the clones can secrete the desired antibody, some of them are non-
secretors or some secrete irrelevant antibody, a screening assay should be developed 
to screen out the positive clones. The practical constraints on screening assays are 
reliability, speed, cost and labor. For soluble antigens, the most popular and 
straightforward approach is ELISA (Kemeny 1991). 
3.1.2.6 Cloning 
The next issue that must be addressed in the production of hybridoma is that of 
clonality. The primary culture after fusion may contain many clones in each well. It 
is essential to separate the specific cells from those contaminating cells to ensure 
monoclonality. Limiting dilution is the most common cloning method (Lefkovits and 
Waldmann 1979). In this method, the cells are diluted to an average of one cell per 
well. If cells are grown in small numbers, the fraction of wells with growth should 
follow the Poisson distribution (Coller and Coller 1983): 
/ 0 ) = e-入 
where y(0) is the fraction of wells with no growth, and X is the average number of 
clones per well. If X = l,f{0) = 0.37. To obtain a reasonable probability that wells 
with growth containing single clones, 37% of wells should have no growth. 
Hybridoma lines should be cloned by limiting dilution at least twice to make 
absolutely certain that each is a true clone. The major problem in this method of 
cloning is that the hybridoma cells cannot grow well at very diluted concentration. 
However, this can be overcome by using feeder cells. Feeder cells, such as 
thymocytes (Lernhardt et al. 1978), normal spleen cells (Galfre and Milstein 1981) 
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and peritoneal cells (Hengartner et al. 1978), are good source of interleukin-6 which 
is an important factor to promote hybridoma growth. 
3.1.2.7 Bulk production of monoclonal antibody 
The most economical method for expanding clones is by in vivo infection. 
Injection of 10^-10^ hybrid cells into mice intraperitoneally will result in tumor 
formation after 2-4 weeks. Ten days before the injection of cells, the mice should be 
primed with 0.5 ml pristane (2,6,10,14-tetramethyl pentadecane) (Freund and Blair 
1982). The antibody level in the ascites fluid can range from 2 to 10 mg/ml and 2 to 
5 ml ascites fluid can be obtained from a mouse. 
3.1.2.8 Monoclonal antibody purification 
The methods available to purify polyclonal antibodies are also suitable for 
monoclonal antibodies purification (Table 3.1). The choice of the purification 
method is often governed by a number of variables, including the species in which it 
was raised, its class and subclass, the properties of the starting material. The main 
contaminants in ascites fluid are mouse serum proteins including substantial amounts 
of mouse albumin and also the mouse irrelevant IgG (Table 3.2). 
3.2 Methods 
3.2.1 Immunization of mice with apolipoprotein A-I and BlOO 
For each antigen (apoA-I or apoB100), seven BALBc mice were immunized 
according to the following schedule: 100 i^l PBS containing 15 i^g of protein was 
emulsified with an equal volume of cFA and injected into each mouse 
intraperitoneally. Fourteen days later the mice were injected with a booster dose of 
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Table 3.1 Methods for purification of antibodies 
Method Examples 
Fractional Precipitation 
Neutral salts Ammonium sulfate, sodium sulfate, 
magnesium sulfate 
Organic solvents Ethanol, polyethylene glycol (PEG) 
Metal ions Zinc 
Short-chain fatty acids Caprylic acid 
Organic cations Rivanol 
Electrophoretic Separation 
Carrier free media Free boundary electrophoresis 
Solid support Zone electrophoresis on cellulose, 
acrylamide, or starch gel 
Isoelectric focusing Liquid media (sucrose gradient), gel media 
(acrylamide) 
Ion-Exchange and Gel Filtration Chromatography 
Anion exchangers Aminoethyl (AE-), diethylaminoethyl 
(DEAE-) and quartemary aminoethyl 
(QAE-) cellulose, Sephadex, or Sepharose 
Cations Carboxymethyl (CM-) cellulose, Sephadex, 
or Sepharose 
Gel filtration Sephadex G series, Sepharose 2B, 4B, 6B 
or CL 2B, CL 4B, CL 6B, Sephacryl S 
series, Biogel agarose or polyacrylamide 
beads, Ultrogel polyacrylamide-agarose 
beads 
Preparative Ultracentrifugation 
Sucrose density gradients, salt gradients 
Affinity Chromatography 
Protein A, protein G, protein AJG, 
thiophilic adsorption, avidin-biotin 
systems, antigen affinity column, anti-
immunoglobulin affinity column, 
hydroxylapatite 
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Table 3.2 Sources for purifying antibodies 
Source Antibody Total Specific Contaminating Possible 
type antibody, antibody, antibodies purity of 
mg/ml mg/ml specific 
antibody 
Serum Polyclonal 10 1 at least Other semm 10% at 
(10% max) antibodies best 
Tissue Culture (in vitro techniques) 
With 10% Monoclonal 1 0.05% (5%) Calfantibody > 95% 
FCS 
Serum- Monoclonal 0.05 0.05 (100%) None > 95% 
free media 
Tissue Culture (in vivo techniques) 
Ascites Monoclonal 1-10 0.9-9(90%) Mouse antibody 90% 
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35 i^g of the protein by the same method but using iFA instead of cFA. Mice were 
totally boosted three times with a fourteen-day interval between each injection. 
3.2.2 Preparation before fusion 
Methods described under this section, unless otherwise specified, were carried 
out in a laminar flow cabinet. Tissue culture reagents were warmed to 37°C before 
use. Cell counts were determined in a hemocytometer. Cells were harvested by 
centrifugation at 1,000 r.p.m. for 5 minutes. Cell cultures were incubated at 37°C 
with an atmosphere of 5.0% CO2. 
3.2.2.1 Preparation of tissue culture working solutions 
Fetal calf serum (FCS) was heat inactivated at 56 °C for 30 minutes in order to 
inactivate serum reactive proteins (e.g. complements) which could damage the cells 
in culture. FCS was dispensed in 25 ml aliquots and stored at -20 °C until to use. 
Powder RPMI obtained from Gilbco was used as the basic culture medium. 
One liter of RPMI was prepared by dissolving a package of RPMI powder (1 Liter) 
in nano-pure water (700 ml). Sodium biocarbonate CNaHCO3, 3.7 g) was added to 
the medium until fully dissolved. The pH of the medium was adjusted to 7.1-7.2 by 
either 1 N HC1 or 1 N NaOH solution. Nano-pure water was then added to bring the 
volume to one liter. The medium was then sterilized by negative pressure filtration 
through a 0.22 i^m pore size filter membrane. The sterilized medium, which is 
referred to a plain medium (P-RPMI), was dispensed into 500 ml air-tight bottles and 
stored at 4 °C prior to use. 
Culture medium which contains FCS, antibiotics and other essential 
components is referred to as complete medium (C-RPMI). Unless otherwise 
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specified, all cells were cultured in C-RPMI (contained 10% heat inactivated FCS, 
50 units/ml penicillin, 50 ^ig/ml streptomycin and 300 ^g/ml L-glutamine). 
Hybridoma selective medium (HAT medium) was C-RPMI supplemented with 
sodium hypoxanthine (0.1 mM), aminopterin (0.4 ^M) and thymidine (1.6 ^iM). 
Hybridoma proliferation medium (HT medium) was the same as HAT medium 
without the aminopterin. 
3.2.2.2 Preparation of spleen cells 
The mouse with the highest titer was chosen and boostered three days before 
fusion with 200 i^l PBS containing 10 i^g antigen intraperitoneally (Shibier et al. 
1988). The immunized mouse was sacrificed by cervical dislocation and swabbed 
with 70% ethanol. The mouse was cut open to expose the spleen. The spleen was 
removed and placed in a 144 x 21 mm sterile Petri dish containing 5 ml C-RPMI. All 
fat was removed from the spleen and then it was transferred into a fresh dish 
containing 5 ml C-RPMI. A 21 G needle mounted on a 1ml syringe was used to tease 
the spleen to release the cells. All the released cells were transferred to a 10 ml 
centrifuge tube and tissue clumps were allowed to settle by standing the tubes for 5 
minutes. The cell suspension was pipetted into a fresh 10 ml tube, without disturbing 
the tissue clumps. The suspension was made up to 10 ml with extra C-RPMI and the 
cells were centrifuged down. The plain supernatant was discarded and the cells pellet 
was resuspended in 10 ml of PBS. The cells were then transferred to a 50 ml culture 
tube and 10 ml sterile water was added to lyze the red blood cells. Immediately, 10 
ml of 2X PBS was added and the cells were washed two times with P-RPMI. The 
spleenocytes were then resuspended in 20 ml C-RPMI and the viability of the cells 
was determined by trypan blue exclusion test: 50 i^l cell suspension was diluted with 
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four volumes of PBS and mixed with 250 i^l 0.2% trypan blue and the viable cell 
number was counted. Around 10^  spleen cells was obtained per mouse, 
3.2.2.3 Preparation of myeloma cells 
The myeloma cell line used in the fusion was P3/NSl/l-Ag4-l fNTS-l). NS-1 
cells are resistant to 10"^  M 8-azaguanine and will not grow in HAT medium. 
However, HAT sensitive myeloma may sometimes revert to HAT resistance due to 
mutation. The reverted cells would decrease the successful growth of the hybrids. In 
order to ensure HAT sensitivity, NS-1 cells were cultured in C-RPMI containing 8-
azaguanine (20 ^ig/ml) for one week before fusion. Two 25 ml flasks ofNS-1 with a 
cell density of 2-3 x 10^  cells/ml were subcultured on the day before fusion and 
maintained at the exponential growth phase. Before fusion, a total of 10? NS-1 cells 
were collected and resuspended in C-RPMI. The cells were washed two times with 
P-RPMI and viability was determined by the trypan blue exclusion test. 
3.2.3 Fusion 
The spleenocytes collected from one spleen was mixed with myeloma cells in a 
50 ml tube in a ratio of 10 spleen cells to 1 myeloma cell. The cell mixture was 
centrifuged and the tube was tapped to losen the cell pellet after removing the 
supernatant. The tube was put into a beaker of water at 3TC and 1 ml ofpre-warmed 
PEG was added slowly over a period of 1 minute, with constant stirring using a 
pipette tip. It is critical that the cells must not be in contact with the concentrated 
PEG solution for more than 2 minutes, otherwise the cell membranes would 
eventually be disrupted. After adding the PEG, 1 ml of P-RPMI was immediately 
added over a period of 1 minute and then a further 4 ml of P-RPMI was added over 
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the next 3-4 minutes. The P-RPMI should be added slowly, without stirring, and 
down by the side of the tube. Then, a further 20 ml of P-RPMI was added following 
by 15 ml of C-RPMI with 20% FCS, again running it slowly down the side of the 
tube. The culture tube was inverted once and left at 37°C for 2 hours, allowing the 
cell membranes to stabilize. Finally, the cells were plated out in 96-well plates with 
100 jid/welL The plates were incubated in the incubator at 37°C with 5% CO2. After 
24 hours, 100 i^l of 2x HAT selection medium was added to each well. After 1 week, 
100 i^l of culture supernatant was removed from each well and replaced with HAT 
selective medium. Growth of hybrid colonies was visible microscopically after 
another several days of incubation (around 10 days after fusion). The growth of 
hybrids would turn the color of the medium to yellow due to the excretion of acidic 
metabolites. When the medium turned yellow, the culture supernatant was replaced 
by new HT medium. 
3.2.4 Screening assay for positive clones 
When the clone grew to cover one forth of the well, 100 i^l of the culture 
medium could be screened to see if it is secreting the desired antibody. Screening 
was performed by standard indirect ELISA (Section 2.2.4) 
3.2.5 Limiting dilution cloning 
All the cells were harvested from the positive well and the cell number was 
counted. The hybridoma was cloned by limiting dilution in which the hybrid cells 
were grown in 96-well plate with a fixed cell density of 1 cell per well. Spleen cells 
from a normal mouse were used as feeder cells. They were prepared by the same 
method as described in the preparation of immunized mice spleenocytes. The feeder 
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cells were washed and resuspended in 4 ml C-RPMI. All dilutions were made by C-
RPML 
Assuming a hybridoma cell concentration of 10^  cells/ml, a 20 i^l of the 
suspension diluted to 2 ml would give a cell density of 1000 cells/ml. 200 i^l of this 
hybridoma suspension was then mixed with 2 ml feeder cells, and diluted to 40 ml to 
give 5 cells/ml. The hybridoma-feeder cell mix was then plated into a in 96-well 
plate at 200 ^l/well. This, in principle, will yield one hybrid cell per well. The cells 
were allowed to grow at 37°C in 5% CO2. This would take about 2 weeks before the 
medium started to turn yellow. Wells with clones were screened by ELISA and 
positive clones were subcloned at least twice until all the clones in one plating 
become positive. The monoclonality is then be ensured at this point. 
3.2.6 Determination of isotype 
The isotype of the monoclonal antibody was determined by indirect ELISA 
using isotype-specific secondary antibodies (Section 2.2.4). These antibodies were 
specific to IgGi, IgG2a, IgG2b, IgG3, IgM, IgA, K-light chain and 入-light chain. 
3.2.7 Cryopreservation of myeloma and established hybridoma cell lines 
3.2.7.1 Freezing cells 
Cryopreservation is necessary to preserve cell lines indefinitely. The cells were 
harvested, counted and centrifuged. The supernatant was discarded and the cells were 
resuspended in cold freezing mixture (90% FCS and 10% dimethyl sulfoxide, 
DMSO) with a cell density of 5xlO^ cells/ml. 1 ml aliquots were transferred into the 
cryotubes and the freezing procedure was started: cells were left in cryotubes on ice 
for 2 hours, then the tubes were wrapped in insulated bubble film, packed in a 
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polystyrene box padded with cotton wool and placed in a -70°C freezer ovemight. 
Finally the box were put into liquid nitrogen tank. 
3.2.7.2 Thawing cells 
Cells were thawed out rapidly in a water-bath maintained at 37°C. 10ml of C-
RPMI was used to dilute the cells. It was important to dilute out the DMSO quickly 
as it would be toxic above 4 °C. The thawed cells were centrifuged down and 
resuspended in fresh C-RPML 
3.2.8 Bulk production of monoclonal antibodies from ascites 
The cloned hybridoma cell line was cultured in vitro in a large scale. At the 
same time, ten BALBc mice were prepared for innoculation by injection with 0.5 ml 
Pristane intraperitoneally. Seven days after the Pristane injection, the hybridoma 
cells were harvested, resuspended in sterile PBS at a concentration between 2xlO^ to 
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2x10 cells/ml and 0.5 ml of the cell suspension was injected intraperitoneally into 
each of the primed mice. The mice were inspected daily for swelling of the abdomen 
(indicating ascitic fluid production). As soon as there was considerable swelling or if 
the mouse was about to die, the mice were killed and the ascitic fluid was collected 
by drawing from a 19G needle fitted syringe. All the cells or fat tissues in the ascites 
fluid were removed by centrifugation. 
3.2.9 Purification of monoclonal antibodies from ascites 
The purification methods for polyclonal antibody (chapter 2.2.5) were used. 
The ascites was diluted two fold with PBS and the protein was precipitated at 45% 
(v/v) ammonium sulfate saturation. The precipitate was centrifuged down and 
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redissolved in PBS (pH8.0). The crude IgG preparation was dialyzed against PBS 
^)H8) at 4°C to remove ammonium sulfate. The antibodies were then purified by 
protein G-Sepharose CL-4B chromatography. PBS was used as the loading buffer 
and 0.1 M citric acid ^)H3.0) as elution buffer. Neutralizing buffer (1.0 M Tris-HCl 
pH9.0) was also used to bring the effluent pH up to around 8 immediately after 
collection of the fractions. 
3.2.10 Western blot analyses of the monoclonal antibodies 
The specificities of AB6 and BE8 were analyzed by westem blotting. 10 ^g of 
apolipoprotein, lipoprotein and 1 i^l of human serum were loaded on SDS-
polyacrylamide gels. After electrophoresis, the proteins were electroblotted onto 
nitrocellulose membranes (0.45 i^m) and the membranes were subsequently blocked 
with PBSMT at room temperature for 2 hours. After washing with PBSMT, the 
membranes were incubated with purified AB6 or BE8 (0.3 ^g/ml in PBSMT) at 4°C 
overnight. The membranes were then washed with PBSMT and incubated in ALP-
conjugated rabbit anti-mouse antibody. 
3.2.11 Iodination of apolipoproteins 
50 i^l apolipoprotein (400 ^ig/ml) dissolved in 0.25 M phosphate buffer ^>H7.4) 
1 ^ c 
was mixed with 10 i^l NaI (1 mCi). The mixture was then added to an iodogen pre-
coated eppendorff tube (2 i^g iodogen in 50 jid dichloromethane and evaporated dry). 
Iodination was performed at room temperature for 11 minutes and 0.5 ml PBS was 
added to stop the reaction. Free iodine was removed by Sep-pak column (C18 
column). The reaction mixture was applied to the column and free iodine was 
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washed out by 50 ml 0.1% trifluoroacetic acid (TFA). The iodinated apolipoprotein 
was eluted with 5 ml 60% acetonitrile in 0.1% TFA. 
3.2.12 Binding of the monoclonal antibody to iodinated apolipoprotein 
Various concentrations of monoclonal antibody (50 i^l) were incubated with 
100 i^l i25i_iabeled apolipoprotein (diluted with 1% BSA in PBS to give 20,000 
c.p.m.) at 4°C overnight. 100 i^l of Sac-cel (anti-mouse IgG antibody-bound cellulose 
bead) was pipetted into the mixture and was allowed to stand at room temperature for 
30 minutes. One ml of distilled water was then added and the suspension was 
centrifuged for 5 minutes at 1,000 g. The supernatant was aspirated and radioactivity 
in the pellet was counted. 
3.2.13 Competitive displacement analysis 
50 i^l of monoclonal antibody in a dilution which gave 50% precipitation of 
i25l-labeled apolipoprotein was mixed with 100 i^l of ^^^I-labeled apolipoprotein 
(20,000 c.p.m.). 50 i^l of various concentrations of unlabeled apoA-I, apoB100, 
HDL, LDL, VLDL, albumin or lipoprotein-depleted human serum (LPDS) were then 
added and incubated overnight at 4°C. Final precipitation with Sac-cel was carried 
out as described above. Maximum binding (Bmax) was determined by replacing the 
unlabeled antigen with PBS. Normal mouse antibody instead of monoclonal antibody 
was used to determine the non-specific binding (Bn.s.). The degree of displacement 
was expressed as B/ Bmax' 
B sample — Bn.s. 
B / Bmax = 
Bmax — Bn.s. 
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The value of B/Bmax will fall within the range of 0 to 1. A smaller value represents a 
higher degree of displacement. 
3.3 Results 
3.3.1 Development of monoclonal antibodies 
Seven mice were immunized with apoA-I and seven were immunized with 
apoB100. The mouse with the highest antibody activity was chosen for fusion 
(Figure 3.3 and 3.4). 
2.3 X 10^  spleenocytes obtained from the apoA-I immunized mouse were fused 
with 2.3 X 10^ of myeloma cells. A total of 89 wells out of 384 wells containing 
growing hybridoma cells were observed. The fusion efficiency was 23.2%. Three of 
these (B6, D9, F2) scored positive upon initial screening by ELISA. During the 
limiting cloning of the anti-apoA-I clones, D9 and F2 lost their specific antibody 
activity and clone B6 was successfully cloned to monoclonality after two subcloning. 
In the second subcloning, 38.5% of the wells did not have hybrid growth and as 
calculated by the Poisson equation, the average number of clones per well was 0.95. 
Since all the hybrids in this round of subcloning were positive for anti-apoA-I 
activity, B6 was probably a homogeneous clone at this stage. 
7 f\ 
In the apoB100 fusion, 3.1 x 10 spleenocytes were fused with 3.1 x 10 
myeloma cells. A total of 91 wells out of 384 wells showed hybrid growth. The 
fusion efficiency was 23.7%. Among these wells, five were screened to be positive; 
A5, B3, B7, E8 and H10. For the cloning of the anti-apoB100 clones, E8 was 
successfully cloned. The other four clones all lost their activities during subcloning. 
After three rounds of subclonings, the calculated average number of clones per well 
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Figure 3.3 Anti-apoA-I antibody (IgG) activity in the sera taken on day 4 after the 
3rd booster of apoA-I injection in seven mice. Anti-apoA-I activity was 
measured by ELISA. 
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Figure 3.4 Anti-apoB100 antibody (IgG) activity in the sera taken on day 4 after 
the 3 booster of apoB100 injection in seven mice. Anti-apoB100 
activity was measured by ELISA. 
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this stage, E8 was probably a homogeneous clone. 
In order to associate the specificities of these monoclonal antibodies against 
different apolipoproteins, clone B6 is named AB6 from hereon to reflect its 
specificity for apoA-I and the clone E8 is named BE8 to reflect its specificity for 
apoB100. By isotyping, both the AB6 and BE8 have IgGi type of heavy chain and 
the K type of light chain. 
3.3.2 Purification of monoclonal antibody from ascites 
Elution profiles for purification of AB6 and BE8 by protein A-Sepharose CL-
4B affinity chromatography are shown in Figure 3.5 and 3.6. In both cases, the 
antibody was eluted in a sharp peak. Figure 3.7 illustrates the purity of AB6 and 
BE8. The purity achieved was almost 100%. By 12.5% SDS-PAGE, the antibodies 
were resolved into two bands. The band with an apparent molecular weight of 55 
kDa was the heavy chain while the band with an molecular weight of 25 kDa was the 
light chain of IgG. 
3.3.3 Western blotting analysis of AB6 and BE8 
The specificities of AB6 and BE8 were confirmed by westem blotting. As 
shown in Figure 3.8, AB6 reacted with a single band in human serum with a 
molecular weight of 28 kDa (Figure 3.8b). AB6 bound only to apoA-I but with no 
activity to other serum proteins. BE8 bound only to apoB100 but not to other LDL 
proteins (Figure 3.9). BE8 also showed no reactivity with other serum proteins in 
immunoblotting with human serum which was separated by 12.5% SDS-PAGE 
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Figure 3.5 Protein G-Sepharose CL-4B chromatography of purification of 
monoclonal antibody AB6. After loading with sample, the column 
was washed with 20 column volumes of PBS at a flow rate of 1 
ml/min. Subsequently, the column was eluted with 0.1 M citric 






§ 1 ‘ 
^ A 
① 0.8 / \ PBS • • Citric acid 
I I \ PH30 
I 0.6 入 
^ L . V 
0 i ^ , ^ ^ ^ 命 會 申 • • $ I • • t J _ , ^ > ^ _ 
0 5 10 15 20 25 30 35 
Elution vol. (ml) 
Figure 3.6 Protein G-Sepharose CL-4B chromatography of purification of 
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Figure 3.7 SDS-Polyacrylamide (12.5%, reducing) gel electrophoresis of 
monoclonal antibodies. (A) standard: albumin, 67 kDa; (B) 
low molecular weight marker; (C) protein precipitate from 
45% ammonium sulfate precipitation of ascites; (D) purified 
AB6; (E) purified BE8. 
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Figure 3.8 Analysis of the specificity of AB6 by SDS-PAGE and 
immunoblotting. (A) Various proteins were separated on 
12.5% SDS-PAGE: 1. Albumin; 2. Low molecular weight 
marker; 3. ApoA-I. (B) Human serum proteins were 
separated on 12.5% SDS-PAGE and transferred to 
nitrocellulose membrane. The membrane was incubated with 
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Figure 3.9 Analysis of the specificity of BE8 by SDS-PAGE and 
immunoblotting. (A) 5% SDS-PAGE of LDL. (B) The 
proteins were blotted onto nitrocelluose membrane and 
incubated with BE8. The reactive band was detected with 
ALP-conjugated secondary antibody 
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3.3.4 Monoclonal antibody titration curve for apolipoproteins by radioimmunoassays 
The binding of ^^^I-labeled apoA-I at different concentrations of monoclonal 
antibody AB6 is shown in Figure 3.10. At low concentrations of AB6, i.e., 200 ng/ml 
to 7 jLig/ml, a linear increase in the binding of ^^^I-labeled apoA-I was observed with 
increasing concentrations of AB6. The maximum binding was obtained at 62.5 jig/ml 
of antibody; however, at higher concentration, a decreased in apoA-I binding was 
observed and this probably indicates a prozone phenomenon. Thus, when the 
concentration of AB6 was increased to 62.5 ^ig/ml, all epitopes on apoA-I were 
saturated and the addition of more AB6 increased the steric interference and reduced 
the interaction between the antibody and apoA-I. 50% of the maximum binding was 
observed when the AB6 concentration was 2 ^ig/ml. 
Figure 3.11 is the binding curve of monoclonal BE8 for ^^^I-labeled apoB100. 
A linear range was obtained from 2 to 30 |ug/ml. Maximum binding was observed at 
300 ^g/ml and 50% of the maximum binding was determined to be at 7^ig/ml of 
BE8. 
3.3.5 Competitive displacement analysis of AB6 and BE8 
Addition studies to characterize the specificities of AB6 and BE8 were carried 
out by competitive displacement analysis. From the results shown in Figure 3.12, the 
addition of LDL, VLDL, BSA or lipoprotein-depleted serum (LPDS) at 
concentrations of 64 ng/ml to 1 mg/ml did not displaced bound ^^^I-labeled apoA-I 
from AB6. On the other hand, apoA-I, HDL and whole serum demonstrated a 
concentration-dependent parallel displacement of apoA-I. The IC50 for apoA-I was 8 
|ig/ml, for HDL was 50 ^ig/ml and for whole serum was 70 ^g/ml. These results 
suggest no cross-reactivity of AB6 with LDL, VLDL, BSA or other serum proteins. 
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Figure 3.11 Titration curve of BE8 by radioimmunoassay. 
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Figure 3.12 Competitive displacement analysis of AB6.Iodinated apoA-I was 
co-incubated with AB6 and various total protein concentrations of 
purified apoA-I, HDL, LDL, VLDL, human whole serum, BSA, 
and lipoprotein-depleted semm (LPDS). The immunocomplex was 
precipitated by Sac-cel and its radioactivity was measured by 
gamma-counter. 
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As depicted in Figure 3.13, the addition of HDL, BSA or LPDS at 
concentrations of 64 ng/ml to 1 mg/ml did not displaced BE8 bound ^^^I-labeled 
apoB100 from BE8. A concentration-dependent parallel displacement of ^^^I-labeled 
apoB100 was observed for apoB100, LDL, VLDL and whole serum. The IC50 for 
apoB100 was 35 jug/ml, LDL was 60 ^ig/ml, VLDL was 70 jug/ml and whole serum 
was 100 j^g/ml. This suggests that no cross-reactivity ofBE8 against HDL, BSA or 
other serum proteins. 
3.4 Discussion 
Two hybridoma fusions were performed for the production of monoclonal 
antibodies against apoA-I and apoB100. In these two fusions, the efficiencies were 
23.2% and 23.7%. Among the successfully fused cells, 3.4% (3 out of89) and 5.5% 
(5 out of 91) were hybridomas secreting antibodies against apoA-I and apoB100, 
respectively. Various fusion efficiencies have been reported in different studies 
ranging from 10% (Berghman et al. 1988) to 90% (Chen et al. 1996). Many 
parameters can influence the fusion efficiency, and the most crucial one is the fusion 
method. Electrofusion (Hewish and Werkmeister 1989) and laser fusion (Wiegand et 
al. 1987) were introduced in the last decade and these methods can significantly 
increase the fusion efficiency. The biotin-avidin method of linking B cells with 
myeloma cells has also been employed to increase fusion efficiency (Wojchowksi 
and Sytkowski 1986). 
From the five apoA-I and three apoB100 positive clones, we were only 
successful in obtaining one clone from each case. The lost of positive clone during 
cloning is not uncommon. The fused cells which carry an initial double load of 
chromosomes tend to take longer to replicate. These cells can lose chromosomes 
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Figure 3.13 Competitive displacement analysis of BE8.Iodinated apoB100 was 
co-incubated with BE8 and various total protein concentrations of 
HDL, LDL, VLDL, human whole semm, BSA, and lipoprotein-
depleted serum (LPDS). The immunocomplex was precipitated by 
Sac-cel and its radioactivity was measured by gamma-counter. 
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very fast and if these chromosomes include mouse chromosome 12, which contains 
the immunoglobulin heavy chain gene, or chromosome 6 which contains the K light 
chain gene, the ability of the fused cells to secrete the appropriate antibody will be 
lost. The second possible explanation is that the screening assay produces false 
positive signal. The unfused B cells which secrete specific antibody can grow in 
selecting medium for a few days, and the positive signal obtained in the initial 
screening may from these unfused B cells. The myeloma cell line used in this study 
may also contribute to the lost of positive hybridomas. NS-1 can synthesize K light 
chain. Although NS-1 cannot secrete free K light chain, it can however, incorporate it 
into a heavy chain and secrets it if the NS-1 is fused with a B cell (Kohler and 
Milstein 1976). In this case, the hybrid antibody molecule will have low or no 
binding affinity for the antigen because it lacks a binding site. The most common 
non-secretor myeloma cell lines are listed in Table 3.3. 
Two monoclonal antibodies, AB6 and BE8, against apoA-I and apoB100, were 
successfully produced and purified in this study. Their relative affinities to their 
respective antigens were determined from their titration curves (Figure 3.10 and 
3.11). For a constant amount of labeled antigen in the reaction, less amount of high 
affinity antibody is required to bind 50% of the antigen than is required by a low 
affinity antibody. Using this a criterion, we can conclude that AB6 has a higher 
affinity to apoA-I than BE8 to apoB100. 
The specificities of AB6 and BE8 were demonstrated by western blotting and 
competitive displacement analysis. Both of these studies showed that AB6 is specific 
to apoA-I and apoA-I-containing lipoprotein while BE8 is specific to apoB100 and 
apoB100-containing lipoproteins. The two monoclonal antibodies show no cross-
reactivity with other lipoproteins or serum proteins. 
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Table 3.3 Commonly used myeloma cell lines in hybridoma production 
Cell line Derived from Fusion efficiency Hybridoma stability 
K light chain secretor 
P3/NSl-Ag4-l 0N S^-1) X63 +++ +++ 
Non-secretor 
P3-X63-Ag8-653 X63 - A g 8 ++ +++ 
Sp2/0-Ag 14 (Sp2) X63 — Ag8 x BALBc ++ +++ 
F0 CloneofSp2 +++ +++ 
NSO/1 NS1 -Ag4-1 j ^ j ^ 
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Apolipoprotein is embedded in the lipid layer of the lipoprotein and it is 
possible to produce a monoclonal antibody with its recognition site shielded by the 
lipid layer. The parallel displacement curves observed for purified apolipoproteins, 
intact lipoproteins and whole serum suggest that AB6 and BE8 recognize these 
entities identically. So it is likely that the recognition site of AB6 and BE8 are 
located on the surface of lipoprotein rather than those epitopes internally shielded by 
lipid layers. 
Many studies have been focused on the conformational states of 
apolipoproteins in lipid-free and lipid-bound states (Jonas 1986; Wetterau and Jonas 
1982). These studies suggest that the conformation of the apolipoproteins are 
different in these two states, and there may be more than one conformation for lipid-
bound apolipoprotein (Jonas et al. 1977; Wetterau and Jonas 1983). The production 
of a monoclonal antibody which can recognize all these conformations with same 
affinity will refine the development of an immunoassay for detecting lipoproteins in 
their natural serum environment. Along this lining reasoning, it is better to use an 
antibody for immunoassay which recognizes free and lipid-bound apoA-I with same 
affinity. This is true, because there are free apoA-I molecules in the serum derived 
from HDL catabolism (Liang et al. 1994; Kunitake et al. 1985). 
In summary, we have produced two hybridoma cell lines for anti-apoA-I and 
anti-apoB100 monoclonal antibodies. These antibodies are only specific to their 
target antigens with no cross-reactivity to other lipoproteins or serum proteins. Their 
recognition sites are probably an apolipoprotein fragment exposed on the surface of 




Enzyme-linked immunosorbent assay (ELISA) for Apolipoprotein A-I 
4.1 Introduction 
Enzyme is one ofthe most versatile labeling substances in immunoassays. The 
term ELISA (enzyme-linked immunosorbent assay) was introduced in 1971 (Engvall 
and Perlmann 1971). The first ELISA for determination of apoA-I was developed in 
1983 (Koritnik and Rudel 1983). More recently, several types ofELISA, either direct 
or competitive, have been reported for apoA-I measurement (Bury and Rosseneu 
1988; Bury and Rosseneu 1985; Dubois et al. 1987; Barkia et al. 1988; Betard et al. 
1987). ELISA is well suited to apolipoproteins measurement because it requires 
small amount of antibody. It does not require the use of radioisotopes and can be 
easily automated. Finally, its accuracy and reproducibility compare well with other 
assays. 
4.1.1 Alkaline phosphatase (ALP) 
ALP (orthophosphoric-monoester phosphorylase, alkaline optimum, E.C. 
3.1.3.1) is one of the most commonly used enzymes in ELISA. It represents a large 
family of isoenzymes. ALP used in ELISA generally comes from bovine intestinal 
mucosa or E. coli. Bovine intestinal ALP has a molecular weight of about 140,000. 
The active site contains two zinc atoms and one magnesium atom, both of them are 
essential for activity (Kim and Wyckoff 1991). The exact biological function ofALP 
is still uncertain. ALP isozymes can cleave phosphomonoester groups from a wide 
variety of substrates. Typical phosphate acceptor additives include diethanolamine, 
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Tris, and 2-amino-2-methyl-1 -propanoL The presence of these additives in substrate 
buffers can dramatically increase the sensitivity of the ELISA. 
ALP is commonly used in ELISA due to its stability. It can withstand 
moderately high temperature and can maintain enzyme activity over extended 
periods of substrate development. 
4.1.2 Conjugation methods 
In a typical sandwich ELISA, antibody is conjugated with an enzyme for the 
detection of the solid phase-bound analyte. In a conjugation reaction, both the 
antibody and enzyme are chemically modified. Functional groups of the two 
molecules are covalently linked together by a bifunctional cross-linker. Cross-linker 
can be classified on the basis of their length, homobifunctional or heterobifunctional, 
and chemically or photochemically reactive. In this study, a heterobifunctional cross-
linker N-Succinimidyl 4-(^-maleimidomethyl)-cyclohexane-1 -carboxylate (SMCC) 
was used to link up the anti-apoA-I antibody with the alkaline phosphatase enzyme. 
SMCC contains an amine-reactive N-hydroxysuccinimide Q^HS) ester on one 
end and a sulfhydryl-reactive maleimide group on the other. SMCC possesses the 
most stable maleimide functional group and allows activation of either enzyme or 
antibody via the amine-reactive NHS ester end. The maleimide-activated 
intermediate can be purified away from excess cross-linker and reacts with the 
second protein (Figure 4.1). The two-step nature of this process limits polymerization 
of the conjugated proteins and provides control over the extent and sites of cross-
linking. 
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Figure 4.1 The reaction of SMCC with the amine group on enzyme 
molecule yields a maleimide-activated derivative capable of 
coupling with sulfhydryl-containing antibody molecules. 
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In this study, the alkaline phosphatase was activated by SMCC and 
subsequently conjugated with the monoclonal antibody. Since antibodies typically do 
not contain free sulfhydryls accessible for conjugation, 2-mercaptoethylamine 
(MEA) can be used to cleave the immunoglobulin molecule into two half each 
possessing one antigen binding site and the requisite sulfhydryls (Figure 4.2). 
4.1.3 Design of the immunoassay format 
In this study, a noncompetitive two-site (sandwich type) immunoassay will be 
developed for the measurement of apoA-I in which a combination ofmonoclonal and 
polyclonal antibodies is used (Figure 4.3). Polyclonal antibody is preferred to be the 
capturing antibody because they can capture the analyte with more than one epitope. 
The rate of dissociation of any one antibody-epitope binding is the same as for a 
simple interaction, but because the antigen is still held by other interactions, the 
overall rate of dissociation is very slow. Monoclonal antibody will be used as the 
detecting antibody because it can offer better specificity than polyclonal antibody. 
Because sandwich immunoassays involve two antibodies, they are more specific than 
competitive assays. Cross-reacting substances which interfere with the competitive 
assays give no signal in sandwich assays, because it is unlikely that they will bind to 
both the capture and the detection antibodies. 
4.1.4 Modified solid-phase: Protein A antibody-capture ELISA (PACE) 
The antibody binding capacity of a polystyrene microtiter plate can be 
increased by coating the wells with protein A or protein G prior to the addition of an 
antibody. The signal strength and sensitivity of many types of ELISA are dependent 
on the amount of antibody available to capture the antigen. When microtiter plates 
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formation. 
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Figure 4.3 Sandwich ELISA using a combination of polyclonal and 
monoclonal antibodies. 
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are pre-coated with proteins A or G, the amount of antibody bound per well can be 
significantly increased leading to the capture of more antigen ps[gai et al. 1993). In 
this study, a new ELISA format, PACE (protein A antibody-capture ELISA), is 
developed for the quantification ofapoA-I. 
4.2 Methods 
4.2.1 Conjugation of AB6 with maleimide activated alkaline phosphatase 
Monoclonal antibody AB6 at a concentration of lmg/ml was dissolved in 
conjugation buffer (0.1 M sodium phosphate, 0.15 M NaCl, pH7.2, containing 10 
mM EDTA). 6 mg of 2-mercaptoethylamine (MEA) was added to the antibody and 
incubated for 90 minutes at 37�C for generating thiol groups in the antibody 
molecules. The reduced AB6 and excess MEA were separated by passing through a 
desalting column. The effluent was collected in 0.5 ml fractions and the protein 
content of each fraction was monitored at 280 nm. The fractions contained antibody 
were pooled together. The antibodies were then mixed with maleimide-activated 
alkaline phosphatase (purchased from Pierce Chemical Company) to obtain the 
desired molar ratio of antibody-to-enzyme (1:4). This ratio was previously 
determined to yield 0.5 to 2 moles of ALPs per mole of IgG. The conjugation 
reaction was performed at room temperature for one hour. 
4.2.2 Titration curve of AB6-ALP conjugate 
Microtiter plates were coated separately with HDL, LDL, VLDL, LPDS, or 
BSA (200 i^l per well with a protein concentration of 25 ^ig/ml). After washing and 
blocking as previously described, 100 i^l of AB6-ALP at various dilutions were 
added. The plates were then incubated at 37�C for two hours. After washing three 
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times with PBSMT and two times with PBST, 100 i^l substrate solution was added to 
assess the amount of enzyme-antibody conjugate bound. 
4.2.3 Calibration curve of apoA-I sandwich ELISA 
Microtiter plates were coated for 16 hours at 4°C with 200 jid of PBS 
containing 2 i^g purified IgG from rabbit anti-apoA-I serum in each well. The plates 
were washed three times with PBSMT and blocked by 1% BSA in PBS. The plates 
were washed three times with PBST to remove excess BSA. Plates prepared in this 
manner could be used for up to one month if stored in a humidified chamber. To 
create the calibration curve, 200 i^l standard apoA-I at concentrations ranging from 
10 ^ig/ml to 9.8 ng/ml was added and incubated at 37°C for an hour. PBS was used 
for dilution. After the plates were washed three times with PBSMT, 100 jid of AB6-
ALP conjugate (100 fold dilution from stock) was added and incubated at 37°C for 
an hour. The unbound conjugate was washed out three times with PBSMT and then 
two times with PBST. 100 i^l freshly prepared substrate solution pNpp was then 
added for color development. The reaction was stopped by adding 50 jal of 0.4 M 
NaOH. Absorbance of the individual wells was determined at 405 nm using a plate 
reader. 
4.2.4 Measurement of apoA-I by Protein A antibody-capture ELISA 
The procedures used in the protein A antibody-capture ELISA was the same as 
the sandwich ELISA except the microtiter plates were pre-coated with Protein A 
before the coating of the capturing antibody,. The protocol of Protein A pre-coating 
is as follow: 50 i^l of Protein A at a concentration of 20 ^ig/ml was added to each 
well. The microtiter plates were then incubated at 37°C for an hour and unabsorbed 
Protein A was washed off by PBST three times. Uncoated sites were blocked by 
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incubating with 100 i^l 1% BSA in PBS at 2>TC for one hour. After washing three 
times with PBST, the plates were ready for coating of the capturing antibody as 
described in section 4.2.2.8. 
4.3 Results 
4.3.1 Characterization of AB6-ALP conjugate 
In order to determine the working dilution of the antibody-enzyme conjugate, a 
binding curve of AB6-ALP to HDL immobilized on microtiter wells was determined 
(Figure 4.4). At 40-fold dilution (with a protein concentration of 101.7 ^g/ml) or 
below, an absorbance of 0.7 was obtained. Beyond 40-fold dilution, activity 
gradually decreased with increasing dilution. When the antibody-ALP conjugate was 
diluted to 2000-fold, absorbance decreased to 0.1. In order to economize on the use 
of the antibody-ALP conjugate for our subsequent assay, a dilution was selected so 
that it will give a reasonable level of sensitivity without using excess amount of the 
reagent. Base on this criterion, the working dilution of the conjugate was established 
to be around 100-fold. Moreover, as shown in Figure 4.4, the conjugate had no cross-
reactivity with other lipoproteins and therefore conjugating AB6 with ALP did not 
seem to have any effects on the specificity of the antibody. 
4.3.2 Calibration curve for the measurement of apoA-I 
Figure 4.5 describes the standard curves for apoA-I determination using 
sandwich ELISA and protein A antibody-capture ELISA (PACE). Both assays were 
able to detect apoA-I level in the range of 0.2 to 1.2 i^g/mL Compared with the 
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The inter- and intra-assay variabilities of the PACE method were determined 
by assaying seven samples, with apoA-I concentrations from 0.4 to 1.0 ^ig/ml, 6 
times on the same day, and on five separate days. As summarized in Table 4.1, the 
mean intra- and inter-assay CVs for the entire assay range were 5.96 and 7.83%, 
respectively. 
4.4 Discussion 
Because of its stability and high sensitivity, alkaline phosphatase was chosen in 
this study to prepare the antibody-enzyme conjugate. The AB6-ALP conjugate had a 
working range between 80- to 120-fold dilution when tested against HDL. Compared 
with commercial preparations of enzyme conjugates, our conjugation efficiency was 
relative low. To increase the efficiency, the reaction time and temperature can be 
prolonged or increased. Moreover, the signal can also be amplified by increasing the 
ratio of enzyme to antibody. However, too many enzymes may have an adverse 
influence on the binding of the antibody to the antigen. 
In this study, we have used a polyclonal antibody preparation and a 
monoclonal antibody-enzyme conjugate to develop a sandwich ELISA for apoA-I 
measurement. The signal strength of this assay was found to be low and it was 
probably due to either the low binding capacity of the polyclonal antibody onto the 
polystyrene microtiter plates or the loss of affinity to the antigen after the antibody 
was adsorbed onto the plastic surface. If these problems were real, protein-A 
antibody capture ELISA may provide a solution for them. Past report showed that the 
wells pre-coated with Protein A could absorb more antibody fNgai et al. 1993). 
Furthermore, since only the Fc fragment binds to protein A, immobilization of the 
capturing antibody in the Fc region can minimize the conformation change ofthe 
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Table 4.1 Precision of Protein A antibody-capture ELISA (PACE) for ApoA-I 
CV, % 
ApoA-I Intra-assay Inter-assay 
concentration, ^g/ml 
0.4 5.37 7.94 
0.5 6.21 8.12 
0.6 6.12 7.11 
0.7 5.84 7.90 
0.8 5.97 7.87 
0.9 6.08 7.81 
1.0 6.11 8.09 
Average ^ T ^ � 
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antigen-binding site. Theoretically, all the antigen-binding sites will face towards the 
solution-phase. Compared to the sandwich ELISA, PACE had significant 
improvement of signal strength, hence indicating our rationalization is probably 
correct. 
In the PACE format, the assay for apoA-I can be finished within three hours. 
Compared to electroimmunoassay, immunoduffusion, or radioimmunoassay, this is a 
significantly faster method. A sensitivity range of 0.2 to 1.2 ^g/ml in our PACE 
assay is probably adequate for the measurement of serum apoA-I since the average 
concentration of apoA-I in human serum is 1.2 g/L; many fold higher than the limits 
of our assay. 
In some previous epidemiological studies, apoA-I and BlOO showed the most 
significant association with the severity of angiographically assessed CHD (Aro et al. 
1986; Noma et al. 1983). Human HDL particles are made up of two major 
populations of particles with different composition and metabolism. Both contain 
apoA-I but only one contains ApoA-II. HDLs that contain only apoA-I (Lipoprotein 
A-I) can increase cellular cholesterol efflux from cultured cells in vitro. HDLs that 
contain both apoA-I and apoA-II (Lipoprotein A-I:A-II), however, do not increase 
cholesterol efflux (Barkia et al. 1991). The ligands that recognize the cell surface 
HDL-binding sites have been identified as apoA-I, apoA-IV, and apoA-II. It is 
proposed that apoA-I and apoA-IV play the role of agonists and apoA-II that of 
antagonist of cholesterol efflux (Barbaras et al. 1990). It is recently shown that 
lipoprotein A-I:A-II can inhibits the lipoprotein A-I promoted cholesterol efflux of 
cholesterol-preloaded adipose cells (Barkia et al. 1991). An assay for HDL will be 
more specific for assessment of CHD risk if lipoprotein A-I:A-II can be removed 
first by anti-apoA-II antibody. 
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The variations of apolipoprotein assay are mainly due to individual differences 
and analytical errors (Evans and Laker 1995). ApoA-I concentrations can increase up 
to 30% (Rifai et aL 1989) and apoB100 up to 60% (Knopp et aL 1985) during 
pregnancy. Smokers have significantly lower apoA-I (-4.2%) (Craig et al. 1989). 
Long-term study in normal subjects has shown that heavy alcohol consumption 
increases apoA-I concentration (Masarei et aL 1986). It is probably due to the 
induction of apolipoprotein synthesis in the liver (Luoma et al. 1982). One of the 
causes of analytical variation in measuring apoA-I level is due to posture. It has been 
shown that apoA-I level will decrease 12% when the subject changes from standing 
to lying (Miller et aL 1992). Altered sympathetic nervous system activity may partly 
explain postural changes (Howes et aL 1987). Different storage methods also 
contribute to assay variations. The concentration of apoA-I increases with the time of 
storage at either room temperature or 4°C. These changes in apparent apoA-I 
concentrations are believed to be from structural changes in HDL leading to altered 
exposure of the antigenic sites (Wang et al. 1989). 
The standard used in this study is pure apoA-I. In order to use the assay for 
semm samples, it should be tested for nonspecific interferences that may affect the 
accuracy and precision of the results. Most of the manifestations of interferences can 
be generally classified as ‘matrix effects'. Serum may contains autoantibodies, 
complement and rheumatoid factor which can lead to a reduction in apparent 
concentration of the analyte. Moreover, serum may contain enzyme inhibitors, 




The contribution of HDL and LDL in the development of atherosclerosis is 
well understood. Their relationships are true both for morbidity (Gordon et aL 1977) 
and mortality (Wilson et aL 1988) from CHD. ApoA-I and apoB100 have been 
suggested to replace HDL- and LDL-cholesterol as better parameters for the 
assessment of CHD risk (Srinivasan and Berenson 1995; Bhatnagar and Durrington 
1991; Laker and Evans 1996). In this study, human serum apoA-I and apoB100 were 
isolated and their antibodies produced. Using these antibodies as immuno-reagents, 
we have attempted to develop ELISA for the measurement of these apolipoproteins. 
A number of ELISA methods for human apoA-I have been published. In these 
studies, the antibodies produced have different binding affinities to lipoproteins and 
free apolipoproteins. It was suggested that sample should be pretreated to expose all 
the antigenic sites before the estimation of the apolipoprotein level. Incubation at 
52°C for 3 hours, denaturation by 6 M guanidine hydrochloride and pretreatment 
with Tween20 are some of the methods that have been suggested. However, these 
pre-treatments are time-consuming and made the assay more complicated, as well as 
subjecting the antibodies to conditions which might affect their binding affinities 
(Wong et al. 1985). Hence, a monoclonal antibody which can bind to the free and 
lipoprotein-bound-apolipoprotein with the same affinity will be a more desirable 
antibody. A monoclonal antibody that can recognize all the possible forms in which 
the apolipoprotein can exist will enhance its utility for detection of apolipoprotein in 
the serum environment without pre-treatment. 
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Another advantage of the ELISA assay developed in this study is the time it 
takes to perform the assay. Three hours is considered to be one of the most rapid 
assays for apoA-I. When compared to electroimmunoassay, immunoduffusion, or 
radioimmunoassay which require several days to be completed, the assay developed 
in this study is more convenient for the clinical use. In the preliminary optimization 
of the assay, the antibody/antigen reaction reached equilibrium after incubation at 
37°C for one hour. Prolonging the incubation time did not increase the signal 
strength significantly (results not shown). AB6 probably has a strong affinity to 
interact with apoA-I. 
Finally, the assay for apoA-I described here offer some other advantages over 
previously described apoA-I immunoassay: no centrifugation steps are required, 
radioisotopes are not used, and the monoclonal antibody which are highly specific is 
available in unlimited supply and in large quantity, and are easily purified. 
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